BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bruix J, Takayama T, Mazzaferro V, Chau G-Y, Yang J, Kudo M, Cai J, Poon RT, Han K-H, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Le Berre Marie-Aude, Meinhardt G, Llovet JM, investigators S. Articles Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16: :1344-1354. [PMID: 26361969 DOI: 10.1016/s1470-2045(15)00198-9] [Cited by in Crossref: 436] [Cited by in F6Publishing: 222] [Article Influence: 62.3] [Reference Citation Analysis]
Number Citing Articles
1 Marron TU, Schwartz M, Corbett V, Merad M. Neoadjuvant Immunotherapy for Hepatocellular Carcinoma. J Hepatocell Carcinoma 2022;9:571-81. [PMID: 35794901 DOI: 10.2147/JHC.S340935] [Reference Citation Analysis]
2 Hatzidakis A, Müller L, Krokidis M, Kloeckner R. Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations. Cancers (Basel) 2022;14:2469. [PMID: 35626073 DOI: 10.3390/cancers14102469] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Greten TF, Lai CW, Li G, Staveley-O'Carroll KF. Targeted and Immune-Based Therapies for Hepatocellular Carcinoma. Gastroenterology 2019;156:510-24. [PMID: 30287171 DOI: 10.1053/j.gastro.2018.09.051] [Cited by in Crossref: 55] [Cited by in F6Publishing: 60] [Article Influence: 13.8] [Reference Citation Analysis]
4 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Kaseb AO, Vence L, Blando J, Yadav SS, Ikoma N, Pestana RC, Vauthey JN, Allison JP, Sharma P. Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma. Cancer Immunol Res 2019;7:1390-5. [PMID: 31289040 DOI: 10.1158/2326-6066.CIR-18-0605] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
6 Zhang H, Xiong F, Qian K, Liu Y, Liang B, Xiong B, Yang F, Zheng C. Transcatheter arterial embolization combined with hypoxia-replicative oncolytic adenovirus perfusion enhances the therapeutic effect of hepatic carcinoma. Cancer Manag Res 2019;11:981-96. [PMID: 30774426 DOI: 10.2147/CMAR.S189208] [Reference Citation Analysis]
7 Hester CA, Yopp AC. Surgical Therapies in Hepatocellular Carcinoma. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 145-67. [DOI: 10.1007/978-3-030-21540-8_8] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Ho WJ, Zhu Q, Durham J, Popovic A, Xavier S, Leatherman J, Mohan A, Mo G, Zhang S, Gross N, Charmsaz S, Lin D, Quong D, Wilt B, Kamel IR, Weiss M, Philosophe B, Burkhart R, Burns WR, Shubert C, Ejaz A, He J, Deshpande A, Danilova L, Stein-O'Brien G, Sugar EA, Laheru DA, Anders RA, Fertig EJ, Jaffee EM, Yarchoan M. Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity. Nat Cancer 2021;2:891-903. [PMID: 34796337 DOI: 10.1038/s43018-021-00234-4] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Roderburg C, Tacke F, Trautwein C. Antiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and Prognosis. Visc Med. 2016;32:121-126. [PMID: 27413730 DOI: 10.1159/000444990] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
10 Zamora-Valdes D, Taner T, Nagorney DM. Surgical Treatment of Hepatocellular Carcinoma. Cancer Control 2017;24:1073274817729258. [PMID: 28975836 DOI: 10.1177/1073274817729258] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
11 Farha M, Jairath NK, Lawrence TS, El Naqa I. Characterization of the Tumor Immune Microenvironment Identifies M0 Macrophage-Enriched Cluster as a Poor Prognostic Factor in Hepatocellular Carcinoma.JCO Clin Cancer Inform. 2020;4:1002-1013. [PMID: 33136432 DOI: 10.1200/CCI.20.00077] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms – Kurzversion 2.00 – Juni 2021, AWMF-Registernummer: 032-053OL. Z Gastroenterol 2022;60:81-107. [PMID: 35042249 DOI: 10.1055/a-1589-7520] [Reference Citation Analysis]
13 Kardashian A, Agopian V. Reply. Hepatology 2020;72:1500. [PMID: 32314409 DOI: 10.1002/hep.31283] [Reference Citation Analysis]
14 Liu Y, Wang Y, Guo X, He Y, Zhou J, Lv Q, Huang X, Li X. Comparative Effectiveness of Adjuvant Treatment for Resected Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis. Front Oncol 2021;11:709278. [PMID: 34540675 DOI: 10.3389/fonc.2021.709278] [Reference Citation Analysis]
15 Li X, Wan J, Wu Z, Tu J, Hu Y, Wu S, Lou L. Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Drug Des Devel Ther 2018;12:3043-9. [PMID: 30271119 DOI: 10.2147/DDDT.S151241] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
16 Xia F, Wu LL, Lau WY, Huan HB, Wen XD, Ma KS, Li XW, Bie P. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients. World J Gastroenterol 2016; 22(23): 5384-5392 [PMID: 27340354 DOI: 10.3748/wjg.v22.i23.5384] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
17 Prasad V, Lindner S. Why is research in early-stage cancer research so low? Journal of Cancer Policy 2018;17:4-8. [DOI: 10.1016/j.jcpo.2018.07.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Hu M, Wang M, Lu H, Wang X, Fang X, Wang J, Ma C, Chen X, Xia H. Loss of miR-1258 contributes to carcinogenesis and progression of liver cancer through targeting CDC28 protein kinase regulatory subunit 1B. Oncotarget 2016;7:43419-31. [PMID: 27270326 DOI: 10.18632/oncotarget.9728] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
19 Vidal-Cevallos P, Chavez-Tapia N. Very-early-stage Hepatocellular Carcinoma, Are We at Long Last on Route for Achieving Better Patient Outcomes? J Clin Transl Hepatol 2021;9:141-2. [PMID: 34007794 DOI: 10.14218/JCTH.2021.00137] [Reference Citation Analysis]
20 Pinato DJ, Cortellini A, Sukumaran A, Cole T, Pai M, Habib N, Spalding D, Sodergren MH, Martinez M, Dhillon T, Tait P, Thomas R, Ward C, Kocher H, Yip V, Slater S, Sharma R. PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma. BMC Cancer 2021;21:301. [PMID: 33757459 DOI: 10.1186/s12885-021-08033-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
21 Sparkman J, Hernaez R, El-Serag HB. Traditional Chinese Medicine to the rescue of allopathic medicine in the co-adjuvant treatment of hepatocellular carcinoma. Transl Gastroenterol Hepatol 2018;3:97. [PMID: 30603733 DOI: 10.21037/tgh.2018.11.05] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
22 Kudo M. Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma. Liver Cancer 2021;10:399-403. [PMID: 34721502 DOI: 10.1159/000518584] [Reference Citation Analysis]
23 Lencioni R, Cioni D. RFA plus lyso-thermosensitive liposomal doxorubicin: in search of the optimal approach to cure intermediate-size hepatocellular carcinoma. Hepat Oncol 2016;3:193-200. [PMID: 30191041 DOI: 10.2217/hep-2016-0005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
24 Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int 2021. [PMID: 34780081 DOI: 10.1111/liv.15101] [Reference Citation Analysis]
25 Brown ZJ, Hewitt DB, Pawlik TM. Experimental drug treatments for hepatocellular carcinoma: Clinical trial failures 2015 to 2021. Expert Opin Investig Drugs 2022. [PMID: 35580650 DOI: 10.1080/13543784.2022.2079491] [Reference Citation Analysis]
26 Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR; AASLD Panel of Experts on Trial Design in HCC. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology 2021;73 Suppl 1:158-91. [PMID: 32430997 DOI: 10.1002/hep.31327] [Cited by in Crossref: 66] [Cited by in F6Publishing: 46] [Article Influence: 66.0] [Reference Citation Analysis]
27 Feng M, Suresh K, Schipper MJ, Bazzi L, Ben-Josef E, Matuszak MM, Parikh ND, Welling TH, Normolle D, Ten Haken RK, Lawrence TS. Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial. JAMA Oncol 2018;4:40-7. [PMID: 28796864 DOI: 10.1001/jamaoncol.2017.2303] [Cited by in Crossref: 70] [Cited by in F6Publishing: 61] [Article Influence: 23.3] [Reference Citation Analysis]
28 Pourhamzeh M, Asadian S, Mirzaei H, Minaei A, Shahriari E, Shpichka A, Es HA, Timashev P, Hassan M, Vosough M. Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma. Mol Cell Biochem 2022. [PMID: 35708866 DOI: 10.1007/s11010-022-04483-4] [Reference Citation Analysis]
29 Kudo M. Proposal of Primary Endpoints for TACE Combination Trials with Systemic Therapy: Lessons Learned from 5 Negative Trials and the Positive TACTICS Trial. Liver Cancer. 2018;7:225-234. [PMID: 30319982 DOI: 10.1159/000492535] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
30 Liu WR, Tian MX, Tao CY, Tang Z, Zhou YF, Song SS, Jiang XF, Wang H, Zhou PY, Qu WF, Fang Y, Ding ZB, Zhou J, Fan J, Shi YH. Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis. BMC Cancer 2020;20:642. [PMID: 32650743 DOI: 10.1186/s12885-020-07138-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Kumar A, Acharya SK, Singh SP, Arora A, Dhiman RK, Aggarwal R, Anand AC, Bhangui P, Chawla YK, Datta Gupta S, Dixit VK, Duseja A, Kalra N, Kar P, Kulkarni SS, Kumar R, Kumar M, Madhavan R, Mohan Prasad VG, Mukund A, Nagral A, Panda D, Paul SB, Rao PN, Rela M, Sahu MK, Saraswat VA, Shah SR, Shalimar, Sharma P, Taneja S, Wadhawan M; INASL Task-Force on Hepatocellular Carcinoma. 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. J Clin Exp Hepatol 2020;10:43-80. [PMID: 32025166 DOI: 10.1016/j.jceh.2019.09.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
32 Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358-80. [PMID: 28130846 DOI: 10.1002/hep.29086] [Cited by in Crossref: 1730] [Cited by in F6Publishing: 1535] [Article Influence: 432.5] [Reference Citation Analysis]
33 Xu M, Zhou Z, Xu R, Zhang H, Lin N, Zhong Y. Antiviral therapy predicts the outcomes following resection of hepatocellular carcinoma in patients negative for HBV DNA: a propensity score matching analysis. World J Surg Oncol 2019;17:45. [PMID: 30823932 DOI: 10.1186/s12957-019-1577-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
34 Kamiyama T, Orimo T, Wakayama K, Kakisaka T, Shimada S, Nagatsu A, Asahi Y, Aiyama T, Kamachi H, Taketomi A. Preventing Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy With Active Hexose-correlated Compound Derived From Lentinula edodes Mycelia. Integr Cancer Ther 2022;21:15347354211073066. [PMID: 35075934 DOI: 10.1177/15347354211073066] [Reference Citation Analysis]
35 Jin M, Yu Q, Liu Y, Xu W, Fu X, Ji B. Safety and Efficacy of Physical Thermal Ablation Combined Sorafenib for Hepatocellular Carcinoma: A Meta-analysis. J Clin Transl Hepatol 2021;9:149-59. [PMID: 34007796 DOI: 10.14218/JCTH.2020.00125] [Reference Citation Analysis]
36 Taniguchi M, Mizuno S, Yoshikawa T, Fujinami N, Sugimoto M, Kobayashi S, Takahashi S, Konishi M, Gotohda N, Nakatsura T. Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis. Cancer Sci. 2020;111:2747-2759. [PMID: 32449239 DOI: 10.1111/cas.14497] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
37 Kudo M. New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma. Int J Clin Oncol. [DOI: 10.1007/s10147-022-02166-0] [Reference Citation Analysis]
38 Tan Y, Xu Q, Wu Z, Zhang W, Li B, Zhang B, Xu X, Zhang B, Yan K, Song J, Lv T, Yang J, Jiang L, Shi Y, Yang J, Yan L. Overexpression of PD-L1 is an Independent Predictor for Recurrence in HCC Patients Who Receive Sorafenib Treatment After Surgical Resection. Front Oncol 2022;11:783335. [DOI: 10.3389/fonc.2021.783335] [Reference Citation Analysis]
39 Parsons HM, Chu Q, Karlitz JJ, Stevens JL, Harlan LC. Adoption of Sorafenib for the Treatment of Advanced-Stage Hepatocellular Carcinoma in Oncology Practices in the United States. Liver Cancer 2017;6:216-26. [PMID: 29234628 DOI: 10.1159/000473862] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
40 Dong W, Yan K, Yu H, Huo L, Xian Z, Zhao Y, Li J, Zhang Y, Cao Z, Fu Y, Cong W, Dong H. Prognostic Nomogram for Sorafenib Benefit in Hepatitis B Virus-Related Hepatocellular Carcinoma After Partial Hepatectomy. Front Oncol 2020;10:605057. [PMID: 33643907 DOI: 10.3389/fonc.2020.605057] [Reference Citation Analysis]
41 Hendriks P, Rietbergen DDD, van Erkel AR, Coenraad MJ, Arntz MJ, Bennink RJ, Braat AE, Crobach ASLP, van Delden OM, van der Hulle T, Klümpen HJ, van der Meer RW, Nijsen JFW, van Rijswijk CSP, Roosen J, Ruijter BN, Smit F, Stam MK, Takkenberg RB, Tushuizen ME, van Velden FHP, de Geus-Oei LF, Burgmans MC; Dutch Hepatocellular Cholangiocarcinoma Group. Study Protocol: Adjuvant Holmium-166 Radioembolization After Radiofrequency Ablation in Early-Stage Hepatocellular Carcinoma Patients-A Dose-Finding Study (HORA EST HCC Trial). Cardiovasc Intervent Radiol 2022. [PMID: 35618860 DOI: 10.1007/s00270-022-03162-7] [Reference Citation Analysis]
42 Samonakis DN, Kouroumalis EA. Systemic treatment for hepatocellular carcinoma: Still unmet expectations. World J Hepatol 2017; 9(2): 80-90 [PMID: 28144389 DOI: 10.4254/wjh.v9.i2.80] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
43 Zheng Z, Guan R, Jianxi W, Zhao Z, Peng T, Liu C, Lin Y, Jian Z, Wu YS. Microvascular Invasion in Hepatocellular Carcinoma: A Review of Its Definition, Clinical Significance, and Comprehensive Management. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/9567041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Yang JD, Malhi H. Green tea consumption: A potential chemopreventive measure for hepatocellular carcinoma? Hepatology 2018;67:10-2. [PMID: 28833368 DOI: 10.1002/hep.29481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
45 Sawada Y, Yoshikawa T, Ofuji K, Yoshimura M, Tsuchiya N, Takahashi M, Nobuoka D, Gotohda N, Takahashi S, Kato Y, Konishi M, Kinoshita T, Ikeda M, Nakachi K, Yamazaki N, Mizuno S, Takayama T, Yamao K, Uesaka K, Furuse J, Endo I, Nakatsura T. Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. Oncoimmunology. 2016;5:e1129483. [PMID: 27467945 DOI: 10.1080/2162402x.2015.1129483] [Cited by in Crossref: 77] [Cited by in F6Publishing: 52] [Article Influence: 12.8] [Reference Citation Analysis]
46 Wang K, Wang C, Jiang H, Zhang Y, Lin W, Mo J, Jin C. Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go. Front Immunol 2021;12:792781. [PMID: 34975896 DOI: 10.3389/fimmu.2021.792781] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Marzi L, Mega A, Gitto S, Pelizzaro F, Seeber A, Spizzo G. Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC. Cancers 2022;14:3332. [DOI: 10.3390/cancers14143332] [Reference Citation Analysis]
48 He X, Peng Y, Zhou Z, Li W. Immune Checkpoint Inhibitor-Based Systemic Therapy Shows Remarkable Curative Effect in a Hepatocellular Carcinoma Patient With Intractable Postoperative Recurrence and Metastases: A Case Report and Literature Review. Front Oncol 2022;12:784224. [PMID: 35372050 DOI: 10.3389/fonc.2022.784224] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Zhu XD, Li KS, Sun HC. Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects. Genes Dis 2020;7:359-69. [PMID: 32884990 DOI: 10.1016/j.gendis.2020.02.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
50 Putzer D, Schullian P, Braunwarth E, Fodor M, Primavesi F, Cardini B, Resch T, Oberhuber R, Maglione M, Margreiter C, Schneeberger S, Stättner S, Öfner-Velano D, Jaschke W, Bale RJ. Integrating interventional oncology in the treatment of liver tumors. Eur Surg 2018;50:117-24. [PMID: 29875800 DOI: 10.1007/s10353-018-0521-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
51 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065] [Cited by in Crossref: 365] [Cited by in F6Publishing: 367] [Article Influence: 91.3] [Reference Citation Analysis]
52 Ke R, Cai Q, Chen Y, Lv L, Jiang Y. Diagnosis and treatment of microvascular invasion in hepatocellular carcinoma. Eur Surg 2020;52:55-68. [DOI: 10.1007/s10353-019-0573-1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
53 Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 2018;68:526-49. [PMID: 28989095 DOI: 10.1016/j.jhep.2017.09.016] [Cited by in Crossref: 198] [Cited by in F6Publishing: 196] [Article Influence: 39.6] [Reference Citation Analysis]
54 Trojan J. Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives. Drugs 2020;80:1203-10. [PMID: 32671719 DOI: 10.1007/s40265-020-01361-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
55 Minami Y, Kudo M. Adjuvant therapy after radical surgery for hepatocellular carcinoma: still an unmet need. Hepatobiliary Surg Nutr 2019;8:414-6. [PMID: 31489318 DOI: 10.21037/hbsn.2019.04.05] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
56 Sun HC, Zhu XD, Zhou J, Gao Q, Shi YH, Ding ZB, Huang C, Qiu SJ, Ren N, Shi GM, Sun J, Ye QH, Huang XW, Yang XR, Fan J. Adjuvant apatinib treatment after resection of hepatocellular carcinoma with portal vein tumor thrombosis: a phase II trial. Ann Transl Med 2020;8:1301. [PMID: 33209881 DOI: 10.21037/atm-20-6181] [Reference Citation Analysis]
57 Kokudo T, Kokudo N. What liver surgeons have achieved in the recent decade for patients with hepatocellular carcinoma? Glob Health Med 2020;2:265-8. [PMID: 33330819 DOI: 10.35772/ghm.2020.01086] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
58 Miyata T, Matsumoto T, Nakao Y, Higashi T, Imai K, Hayashi H, Nitta H, Chikamoto A, Beppu T, Yamashita YI, Baba H. Major postoperative complications are associated with early recurrence of hepatocellular carcinoma following hepatectomy. Langenbecks Arch Surg 2022. [PMID: 35441947 DOI: 10.1007/s00423-022-02513-9] [Reference Citation Analysis]
59 Lischalk JW, Repka MC, Unger K. Radiation therapy for hepatobiliary malignancies. J Gastrointest Oncol. 2017;8:279-292. [PMID: 28480067 DOI: 10.21037/jgo.2016.08.02] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
60 Muranushi R, Araki K, Yokobori T, Chingunjav B, Hoshino K, Dolgormaa G, Hagiwara K, Yamanaka T, Ishii N, Tsukagoshi M, Igarashi T, Watanabe A, Kubo N, Harimoto N, Shimoda Y, Sano R, Oyama T, Saeki H, Shirabe K. High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence. Cancer Sci 2021;112:3314-23. [PMID: 34080242 DOI: 10.1111/cas.15004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Kudo M. A Paradigm Change in the Treatment Strategy for Hepatocellular Carcinoma. Liver Cancer 2020;9:367-77. [PMID: 32999864 DOI: 10.1159/000507934] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
62 Shetty K, He AR. A STORM in a teacup?-the challenges of adjuvant therapy in hepatocellular carcinoma (HCC). Transl Gastroenterol Hepatol 2016;1:2. [PMID: 28138570 DOI: 10.21037/tgh.2016.03.10] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
63 Zhong JH, Du XK, Xiang BD, Li LQ. Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial. World J Hepatol 2016; 8(23): 957-960 [PMID: 27621761 DOI: 10.4254/wjh.v8.i23.957] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
64 Zhong JH. The STORM trial and beyond: narrowing the horizon of adjuvant sorafenib for postoperative hepatocellular carcinoma. Tumour Biol. 2015;36:8271-8272. [PMID: 26499777 DOI: 10.1007/s13277-015-4279-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
65 Ho CH, Chuang HC, Wu IC, Tsai HW, Lin YJ, Sun HY, Young KC, Chiu YC, Cheng PN, Liu WC, Tan TH, Chang TT. Prediction of early hepatocellular carcinoma recurrence using germinal center kinase-like kinase. Oncotarget 2016;7:49765-76. [PMID: 27343552 DOI: 10.18632/oncotarget.10176] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
66 Pollom EL, Lee K, Durkee BY, Grade M, Mokhtari DA, Wahl DR, Feng M, Kothary N, Koong AC, Owens DK, Goldhaber-Fiebert J, Chang DT. Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study. Radiology 2017;283:460-8. [PMID: 28045603 DOI: 10.1148/radiol.2016161509] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
67 Kyrochristos ID, Glantzounis GK, Ziogas DE, Gizas I, Schizas D, Lykoudis EG, Felekouras E, Machairas A, Katsios C, Liakakos T, Cho WC, Roukos DH. From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers. Int J Mol Sci 2017;18:E180. [PMID: 28106782 DOI: 10.3390/ijms18010180] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
68 Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey J, Lee SS, Yavuz BG, Mohamed YI, Qayyum A, Jindal S, Duan F, Basu S, Yadav SS, Nicholas C, Sun JJ, Singh Raghav KP, Rashid A, Carter K, Chun YS, Tzeng CD, Sakamuri D, Xu L, Sun R, Cristini V, Beretta L, Yao JC, Wolff RA, Allison JP, Sharma P. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(21)00427-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
69 Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203-217. [PMID: 28053342 DOI: 10.1038/nrgastro.2016.193] [Cited by in Crossref: 194] [Cited by in F6Publishing: 178] [Article Influence: 38.8] [Reference Citation Analysis]
70 Hu J, Mao F, Li L, Wang X, Cai D, He L, Wu Q, Wang C, Zhang N, Ma Y, Wu X, Qu K, Wang X. Analysis of the Heterogeneity of the Tumor Microenvironment and the Prognosis and Immunotherapy Response of Different Immune Subtypes in Hepatocellular Carcinoma. J Oncol 2022;2022:1087399. [PMID: 35401750 DOI: 10.1155/2022/1087399] [Reference Citation Analysis]
71 Jing CY, Fu YP, Zheng SS, Yi Y, Shen HJ, Huang JL, Xu X, Lin JJ, Zhou J, Fan J, Ren ZG, Qiu SJ, Zhang BH. Prognostic nomogram for patients with hepatocellular carcinoma underwent adjuvant transarterial chemoembolization following curative resection. Medicine (Baltimore) 2017;96:e6140. [PMID: 28296727 DOI: 10.1097/MD.0000000000006140] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
72 Kudo M. Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update. Liver Cancer 2020;9:640-62. [PMID: 33442538 DOI: 10.1159/000511001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
73 Jeong YH, Hwang S, Lee GD, Choi SH, Kim HR, Kim YH, Park SI, Kim DK. Surgical Outcome of Pulmonary Metastasectomy for Hepatocellular Carcinoma Recurrence in Liver Transplant Patients. Ann Transplant 2021;26:e930383. [PMID: 33972494 DOI: 10.12659/AOT.930383] [Reference Citation Analysis]
74 Xie DY, Fan HK, Ren ZG, Fan J, Gao Q. Identifying Clonal Origin of Multifocal Hepatocellular Carcinoma and Its Clinical Implications. Clin Transl Gastroenterol 2019;10:e00006. [PMID: 30829920 DOI: 10.14309/ctg.0000000000000006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
75 Gu H, Li J, You N, Wu K, Wang Z, Wang L, Zhu Y, Liu Q, Peng X, Zheng L. Efficacy and safety of apatinib combined with transarterial chemoembolization (TACE) in treating patients with recurrent hepatocellular carcinoma. Ann Transl Med 2020;8:1677. [PMID: 33490189 DOI: 10.21037/atm-20-7244] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Braunwarth E, Stättner S, Fodor M, Cardini B, Resch T, Oberhuber R, Putzer D, Bale R, Maglione M, Margreiter C, Schneeberger S, Öfner D, Primavesi F. Surgical techniques and strategies for the treatment of primary liver tumours: hepatocellular and cholangiocellular carcinoma. Eur Surg 2018;50:100-12. [PMID: 29875798 DOI: 10.1007/s10353-018-0537-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
77 Wan L, Dong DH, Wu XN, Ding HF, Lu Q, Tian Y, Zhang XF, Li W. Single Large Nodule (>5 cm) Prognosis in Hepatocellular Carcinoma: Kinship with Barcelona Clinic Liver Cancer (BCLC) Stage A or B? Med Sci Monit 2020;26:e926797. [PMID: 33060558 DOI: 10.12659/MSM.926797] [Reference Citation Analysis]
78 Tovoli F, De Lorenzo S, Trevisani F. Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now? Vaccines (Basel) 2020;8:E578. [PMID: 33023131 DOI: 10.3390/vaccines8040578] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
79 Maki H, Hasegawa K. Advances in the surgical treatment of liver cancer. Biosci Trends 2022. [PMID: 35732434 DOI: 10.5582/bst.2022.01245] [Reference Citation Analysis]
80 Olesinski J, Mithieux F, Guillaud O, Hilleret MN, Lombard-Bohas C, Henry L, Boillot O, Walter T, Partensky C, Paliard P, Valette PJ, Vuillez JP, Borson-Chazot F, Scoazec JY, Dumortier J. Survival and prognostic factors after adjuvant 131iodine-labeled lipiodol for hepatocellular carcinoma: a retrospective analysis of 106 patients over 20 years. Ann Nucl Med 2017;31:379-89. [PMID: 28342103 DOI: 10.1007/s12149-017-1165-4] [Reference Citation Analysis]
81 Zhu XD, Sun HC. Emerging agents and regimens for hepatocellular carcinoma. J Hematol Oncol. 2019;12:110. [PMID: 31655607 DOI: 10.1186/s13045-019-0794-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 11.7] [Reference Citation Analysis]
82 von Felden J, Schulze K, Gil-Ibanez I, Werner T, Wege H. First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma-An Update on Patient Selection and Response Evaluation. Diagnostics (Basel) 2016;6:E44. [PMID: 27916795 DOI: 10.3390/diagnostics6040044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
83 Fok AJ, She WH, Ma KW, Tsang SHY, Dai WC, Chan ACY, Lo CM, Cheung TT. Adjuvant transarterial chemotherapy for margin-positive resection of hepatocellular carcinoma-a propensity score matched analysis. Langenbecks Arch Surg 2021. [PMID: 34406489 DOI: 10.1007/s00423-021-02292-9] [Reference Citation Analysis]
84 Peng Z, Wu X, Li J, Pang H, Zhang Y, Lin M, Wang Z, Xiao H, Li B, Chen M, Feng S, Kuang M, Chen S. The role of neoadjuvant conventional transarterial chemoembolization with radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma after initial hepatectomy with microvascular invasion. Int J Hyperthermia 2022;39:688-96. [PMID: 35469522 DOI: 10.1080/02656736.2022.2051613] [Reference Citation Analysis]
85 Zahavi T, Lanton T, Divon MS, Salmon A, Peretz T, Galun E, Axelrod JH, Sonnenblick A. Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model. Oncotarget 2016;7:4860-70. [PMID: 26695439 DOI: 10.18632/oncotarget.6638] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
86 Cisneros-garza L, González-huezo M, López-cossio J, Kuljacha-gastelum A. Characterization of hepatocellular carcinoma in Mexico. Revista de Gastroenterología de México (English Edition) 2018;83:223-7. [DOI: 10.1016/j.rgmxen.2017.06.005] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
87 Angelico R, Grimaldi C, Saffioti MC, Castellano A, Spada M. Hepatocellular carcinoma in children: hepatic resection and liver transplantation. Transl Gastroenterol Hepatol 2018;3:59. [PMID: 30363724 DOI: 10.21037/tgh.2018.09.05] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
88 Wang C, Li Q, Xiao B, Fang H, Huang B, Huang F, Wang Y. Luteolin enhances the antitumor efficacy of oncolytic vaccinia virus that harbors IL-24 gene in liver cancer cells. J Clin Lab Anal 2021;35:e23677. [PMID: 33274495 DOI: 10.1002/jcla.23677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
89 Brown ZJ, Gregory S, Hewitt DB, Iacono S, Choe J, Labiner HE, Pawlik TM. Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma. Surgical Oncology 2022;42:101748. [DOI: 10.1016/j.suronc.2022.101748] [Reference Citation Analysis]
90 Nishida N. Long-term prognosis and management of hepatocellular carcinoma after curative treatment. Clin Mol Hepatol 2020;26:480-3. [PMID: 32951413 DOI: 10.3350/cmh.2020.0208] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
91 Dhanasekaran R, Kwo PY. Hepatitis C and Hepatocellular Cancer: To Treat or Not to Treat. Clin Liver Dis (Hoboken) 2021;17:169-73. [PMID: 33868660 DOI: 10.1002/cld.1003] [Reference Citation Analysis]
92 Pearson AD, Gaspar N, Janeway K, Campbell-Hewson Q, Lawlor ER, Copland C, Karres D, Norga K, Benzaghou F, Weiner S, Weigel B, Weiss AR, Strauss SJ, Smith M, Setty BA, Seibel N, Scobie N, Pappo A, Okpara CE, Nysom K, McDonough J, Marshall LV, Ludwinski D, Ligas F, Lesa G, Knudsen S, Kauh J, Hsieh A, Heenen D, Hawkins DS, Graham A, Garmey E, DuBois SG, Fox E, Donoghue M, de Rojas T, Chung J, Casanova M, Brennan B, Bishop M, Buenger V, Reaman G, Vassal G. Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer 2022;173:71-90. [PMID: 35863108 DOI: 10.1016/j.ejca.2022.06.008] [Reference Citation Analysis]
93 Leoni S, Sansone V, Lorenzo S, Ielasi L, Tovoli F, Renzulli M, Golfieri R, Spinelli D, Piscaglia F. Treatment of Combined Hepatocellular and Cholangiocarcinoma. Cancers (Basel) 2020;12:E794. [PMID: 32224916 DOI: 10.3390/cancers12040794] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
94 Ye H, Zhou L, Jin H, Chen Y, Cheng D, Jiang Y. Sorafenib-Loaded Long-Circulating Nanoliposomes for Liver Cancer Therapy. Biomed Res Int 2020;2020:1351046. [PMID: 32461962 DOI: 10.1155/2020/1351046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
95 Petrowsky H, Fritsch R, Guckenberger M, De Oliveira ML, Dutkowski P, Clavien P. Modern therapeutic approaches for the treatment of malignant liver tumours. Nat Rev Gastroenterol Hepatol 2020;17:755-72. [DOI: 10.1038/s41575-020-0314-8] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 27.5] [Reference Citation Analysis]
96 Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, Han G, Wang M, Liu R, Lu L, Ren Z, Chen M, Zeng Z, Liang P, Liang C, Chen M, Yan F, Wang W, Ji Y, Yun J, Cai D, Chen Y, Cheng W, Cheng S, Dai C, Guo W, Hua B, Huang X, Jia W, Li Y, Li Y, Liang J, Liu T, Lv G, Mao Y, Peng T, Ren W, Shi H, Shi G, Tao K, Wang W, Wang X, Wang Z, Xiang B, Xing B, Xu J, Yang J, Yang J, Yang Y, Yang Y, Ye S, Yin Z, Zhang B, Zhang B, Zhang L, Zhang S, Zhang T, Zhao Y, Zheng H, Zhu J, Zhu K, Liu R, Shi Y, Xiao Y, Dai Z, Teng G, Cai J, Wang W, Cai X, Li Q, Shen F, Qin S, Dong J, Fan J. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer 2020;9:682-720. [PMID: 33442540 DOI: 10.1159/000509424] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
97 Zhang Q, Su R, Shan C, Gao C, Wu P. Non-SMC Condensin I Complex, Subunit G (NCAPG) is a Novel Mitotic Gene Required for Hepatocellular Cancer Cell Proliferation and Migration. Oncol Res. 2018;26:269-276. [PMID: 29046167 DOI: 10.3727/096504017x15075967560980] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
98 Fan Y, Xue H, Zheng H. Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. JHC 2022;Volume 9:233-63. [DOI: 10.2147/jhc.s358082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Merchante N, Rodríguez-Arrondo F, Revollo B, Merino E, Ibarra S, Galindo MJ, Montero M, García-Deltoro M, Rivero-Juárez A, Téllez F, Delgado-Fernández M, Ríos-Villegas MJ, García MA, Vera-Méndez FJ, Ojeda-Burgos G, López-Ruz MA, Metola L, Omar M, Alemán-Valls MR, Aguirrebengoa K, Portu J, Raffo M, Macías J, Pineda JA; GEHEP-002 Study Group. Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients. AIDS 2018;32:1423-30. [PMID: 29596108 DOI: 10.1097/QAD.0000000000001809] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
100 Abdel-Rahman O, Cheung WY. The Expanding Role of Systemic Therapy in the Management of Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2018;2018:4763832. [PMID: 30159302 DOI: 10.1155/2018/4763832] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
101 Li H, Yang C, Shi Y, Zhao L. Exosomes derived from siRNA against GRP78 modified bone-marrow-derived mesenchymal stem cells suppress Sorafenib resistance in hepatocellular carcinoma. J Nanobiotechnology 2018;16:103. [PMID: 30572882 DOI: 10.1186/s12951-018-0429-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 7.3] [Reference Citation Analysis]
102 Swamy SG, Kameshwar VH, Shubha PB, Looi CY, Shanmugam MK, Arfuso F, Dharmarajan A, Sethi G, Shivananju NS, Bishayee A. Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma. Target Oncol 2017;12:1-10. [PMID: 27510230 DOI: 10.1007/s11523-016-0452-7] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 10.2] [Reference Citation Analysis]
103 Shimizu T, Ishizuka M, Park KH, Shiraki T, Sakuraoka Y, Mori S, Iso Y, Kato M, Aoki T, Kubota K. Preoperative lymphocyte-to-monocyte ratio is useful for stratifying the prognosis of hepatocellular carcinoma patients with a low Cancer of the Liver Italian Program score undergoing curative resection. Ann Gastroenterol Surg 2019;3:325-35. [PMID: 31131362 DOI: 10.1002/ags3.12251] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
104 Li C, Fu Q, Cai J, Mei H, Shangguan W. Effects of propofol on the proliferation and migration of liver cancer cells. Exp Ther Med 2021;22:733. [PMID: 34055050 DOI: 10.3892/etm.2021.10165] [Reference Citation Analysis]
105 Kim HY, Park JW. Current immunotherapeutic strategies in hepatocellular carcinoma: recent advances and future directions. Therap Adv Gastroenterol 2017;10:805-14. [PMID: 29051790 DOI: 10.1177/1756283X17722061] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
106 Luo B, Liu L, Bi J, Bao S, Zhang Y. Role of the pre- to postoperative alpha-fetoprotein ratio in the prognostic evaluation of liver cancer after radiofrequency ablation. Int J Biol Markers 2022;:3936155221101075. [PMID: 35686334 DOI: 10.1177/03936155221101075] [Reference Citation Analysis]
107 Buonomo AR, Gentile I, Borgia G. Direct acting antiviral agents and hepatocellular carcinoma development: don't take it for granted. Transl Gastroenterol Hepatol 2017;2:101. [PMID: 29264439 DOI: 10.21037/tgh.2017.11.09] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
108 Athuluri-Divakar SK, Hoshida Y. Generic chemoprevention of hepatocellular carcinoma. Ann N Y Acad Sci 2019;1440:23-35. [PMID: 30221358 DOI: 10.1111/nyas.13971] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
109 Xu LX, He MH, Dai ZH, Yu J, Wang JG, Li XC, Jiang BB, Ke ZF, Su TH, Peng ZW, Guo Y, Chen ZB, Chen SL, Peng S, Kuang M. Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma. Ann Oncol. 2019;. [PMID: 30916311 DOI: 10.1093/annonc/mdz103] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 9.5] [Reference Citation Analysis]
110 Cardarelli-Leite L, Hadjivassiliou A, Klass D, Chung J, Ho SGF, Lim HJ, Kim PTW, Mujoomdar A, Liu DM. Current locoregional therapies and treatment strategies in hepatocellular carcinoma. Curr Oncol 2020;27:S144-51. [PMID: 33343208 DOI: 10.3747/co.27.7171] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
111 Foerster F, Hess M, Gerhold-Ay A, Marquardt JU, Becker D, Galle PR, Schuppan D, Binder H, Bockamp E. The immune contexture of hepatocellular carcinoma predicts clinical outcome. Sci Rep 2018;8:5351. [PMID: 29599491 DOI: 10.1038/s41598-018-21937-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 10.5] [Reference Citation Analysis]
112 Allaire M, Goumard C, Lim C, Le Cleach A, Wagner M, Scatton O. New frontiers in liver resection for hepatocellular carcinoma. JHEP Rep. 2020;2:100134. [PMID: 32695968 DOI: 10.1016/j.jhepr.2020.100134] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
113 Kaestner B, Spicher K, Jaehde U, Enzmann H. Effects of sorafenib and cisplatin on preneoplastic foci of altered hepatocytes in fetal turkey liver. Toxicol Res (Camb) 2017;6:54-62. [PMID: 30090476 DOI: 10.1039/c6tx00342g] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
114 Siu EH, Chan AW, Chong CC, Chan SL, Lo KW, Cheung ST. Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment. Transl Gastroenterol Hepatol. 2018;3:89. [PMID: 30603725 DOI: 10.21037/tgh.2018.10.16] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
115 Zhai W, Lai H, Kaya NA, Chen J, Yang H, Lu B, Lim JQ, Ma S, Chew SC, Chua KP, Alvarez JJS, Chen PJ, Chang MM, Wu L, Goh BKP, Chung AY, Chan CY, Cheow PC, Lee SY, Kam JH, Kow AW, Ganpathi IS, Chanwat R, Thammasiri J, Yoong BK, Ong DB, de Villa VH, Dela Cruz RD, Loh TJ, Wan WK, Zeng Z, Skanderup AJ, Pang YH, Madhavan K, Lim TK, Bonney G, Leow WQ, Chew V, Dan YY, Tam WL, Toh HC, Foo RS, Chow PK. Dynamic phenotypic heterogeneity and the evolution of multiple RNA subtypes in hepatocellular carcinoma: the PLANET study. Natl Sci Rev 2022;9:nwab192. [PMID: 35382356 DOI: 10.1093/nsr/nwab192] [Reference Citation Analysis]
116 Huber TC, Bochnakova T, Koethe Y, Park B, Farsad K. Percutaneous Therapies for Hepatocellular Carcinoma: Evolution of Liver Directed Therapies. J Hepatocell Carcinoma 2021;8:1181-93. [PMID: 34589446 DOI: 10.2147/JHC.S268300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Llovet JM, Villanueva A. Effect of HCV clearance with direct-acting antiviral agents on HCC. Nat Rev Gastroenterol Hepatol 2016;13:561-2. [DOI: 10.1038/nrgastro.2016.140] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 8.2] [Reference Citation Analysis]
118 Kirstein MM, Scheiner B, Pinter M, Vogel A. Letter: sequential or combined systemic treatment for unresectable hepatocellular carcinoma-authors' reply. Aliment Pharmacol Ther 2020;52:917-8. [PMID: 32852807 DOI: 10.1111/apt.15980] [Reference Citation Analysis]
119 Matsukuma S, Eguchi H, Wada H, Noda T, Shindo Y, Tokumitsu Y, Matsui H, Takahashi H, Kobayashi S, Nagano H. Liver resection with thrombectomy for patients with hepatocellular carcinoma and tumour thrombus in the inferior vena cava or right atrium. BJS Open 2020;4:241-51. [PMID: 32012492 DOI: 10.1002/bjs5.50258] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
120 Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW, Yoon JH. Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. Cancer Immunol Immunother. 2019;68:23-32. [PMID: 30232520 DOI: 10.1007/s00262-018-2247-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
121 Sherman M. Regorafenib for treatment of hepatocellular carcinoma. Hepatology 2018;67:1162-5. [PMID: 29059458 DOI: 10.1002/hep.29598] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
122 Lupo G, Caporarello N, Olivieri M, Cristaldi M, Motta C, Bramanti V, Avola R, Salmeri M, Nicoletti F, Anfuso CD. Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine. Front Pharmacol. 2016;7:519. [PMID: 28111549 DOI: 10.3389/fphar.2016.00519] [Cited by in Crossref: 27] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
123 Xu J, Xiao X, Yan B, Yuan Q, Dong X, Du Q, Zhang J, Shan L, Ding Z, Zhou L, Efferth T. Green tea-derived theabrownin induces cellular senescence and apoptosis of hepatocellular carcinoma through p53 signaling activation and bypassed JNK signaling suppression. Cancer Cell Int 2022;22. [DOI: 10.1186/s12935-022-02468-3] [Reference Citation Analysis]
124 Wörns MA, Galle PR, Zeuzem S, Schirmacher P, Manns M, Vogel A. Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk. Dtsch Arztebl Int 2017;114:597-602. [PMID: 28927498 DOI: 10.3238/arztebl.2017.0597] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
125 Welling TH, Eddinger K, Carrier K, Zhu D, Kleaveland T, Moore DE, Schaubel DE, Abt PL. Multicenter Study of Staging and Therapeutic Predictors of Hepatocellular Carcinoma Recurrence Following Transplantation. Liver Transpl. 2018;24:1233-1242. [PMID: 29729113 DOI: 10.1002/lt.25194] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
126 Yin D, Wangensteen KJ. Incapacitated Capicua in Sorafenib-Resistant HCC. Cell Mol Gastroenterol Hepatol 2020;10:428-9. [PMID: 32353381 DOI: 10.1016/j.jcmgh.2020.03.007] [Reference Citation Analysis]
127 Pelizzaro F, Gambato M, Gringeri E, Vitale A, Cillo U, Farinati F, Burra P, Russo FP. Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Cancers (Basel) 2021;13:4882. [PMID: 34638365 DOI: 10.3390/cancers13194882] [Reference Citation Analysis]
128 Xia H, Li F, Hu X, Park W, Wang S, Jang Y, Du Y, Baik S, Cho S, Kang T, Kim DH, Ling D, Hui KM, Hyeon T. pH-Sensitive Pt Nanocluster Assembly Overcomes Cisplatin Resistance and Heterogeneous Stemness of Hepatocellular Carcinoma. ACS Cent Sci 2016;2:802-11. [PMID: 27924308 DOI: 10.1021/acscentsci.6b00197] [Cited by in Crossref: 77] [Cited by in F6Publishing: 66] [Article Influence: 12.8] [Reference Citation Analysis]
129 Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten TF, Nault JC, Avila MA. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. Gut 2018;67:380-8. [PMID: 29150490 DOI: 10.1136/gutjnl-2017-315068] [Cited by in Crossref: 92] [Cited by in F6Publishing: 88] [Article Influence: 23.0] [Reference Citation Analysis]
130 Yin H, Sun L, Pu Y, Yu J, Feng W, Dong C, Zhou B, Du D, Zhang Y, Chen Y, Xu H. Ultrasound-Controlled CRISPR/Cas9 System Augments Sonodynamic Therapy of Hepatocellular Carcinoma. ACS Cent Sci 2021;7:2049-62. [PMID: 34963897 DOI: 10.1021/acscentsci.1c01143] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
131 Iyer RV, Maguire O, Kim M, Curtin LI, Sexton S, Fisher DT, Schihl SA, Fetterly G, Menne S, Minderman H. Dose-Dependent Sorafenib-Induced Immunosuppression Is Associated with Aberrant NFAT Activation and Expression of PD-1 in T Cells. Cancers (Basel). 2019;11. [PMID: 31100868 DOI: 10.3390/cancers11050681] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
132 Li YC, Chen PH, Yeh JH, Hsiao P, Lo GH, Tan T, Cheng PN, Lin HY, Chen YS, Hsieh KC, Hsieh PM, Lin CW. Clinical outcomes of surgical resection versus radiofrequency ablation in very-early-stage hepatocellular carcinoma: a propensity score matching analysis. BMC Gastroenterol 2021;21:418. [PMID: 34749663 DOI: 10.1186/s12876-021-01995-z] [Reference Citation Analysis]
133 Facciorusso A, Abd El Aziz MA, Tartaglia N, Ramai D, Mohan BP, Cotsoglou C, Pusceddu S, Giacomelli L, Ambrosi A, Sacco R. Microwave Ablation Versus Radiofrequency Ablation for Treatment of Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials. Cancers (Basel) 2020;12:E3796. [PMID: 33339274 DOI: 10.3390/cancers12123796] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
134 da Fonseca LG, Araujo RLC. Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities. World J Gastroenterol 2022; 28(28): 3573-3585 [DOI: 10.3748/wjg.v28.i28.3573] [Reference Citation Analysis]
135 Mokdad AA, Singal AG, Yopp AC. Advances in Local and Systemic Therapies for Hepatocellular Cancer. Curr Oncol Rep 2016;18:9. [PMID: 26769114 DOI: 10.1007/s11912-015-0494-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
136 Craciun L, de Wind R, Demetter P, Lucidi V, Bohlok A, Michiels S, Bouazza F, Vouche M, Tancredi I, Verset G, Garaud S, Naveaux C, Galdon MG, Gallo KW, Hendlisz A, Derijckere ID, Flamen P, Larsimont D, Donckier V. Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy. BMC Cancer 2020;20:135. [PMID: 32075608 DOI: 10.1186/s12885-020-6613-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
137 Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723-50. [PMID: 29624699 DOI: 10.1002/hep.29913] [Cited by in Crossref: 1646] [Cited by in F6Publishing: 1401] [Article Influence: 411.5] [Reference Citation Analysis]
138 Chen Q, Shu C, Laurence AD, Chen Y, Peng BG, Zhen ZJ, Cai JQ, Ding YT, Li LQ, Zhang YB, Zheng QC, Xu GL, Li B, Zhou WP, Cai SW, Wang XY, Wen H, Peng XY, Zhang XW, Dai CL, Bie P, Xing BC, Fu ZR, Liu LX, Mu Y, Zhang L, Zhang QS, Jiang B, Qian HX, Wang YJ, Liu JF, Qin XH, Li Q, Yin P, Zhang ZW, Chen XP. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial. Gut 2018;67:2006-16. [PMID: 29802174 DOI: 10.1136/gutjnl-2018-315983] [Cited by in Crossref: 68] [Cited by in F6Publishing: 74] [Article Influence: 17.0] [Reference Citation Analysis]
139 Juratli MA, Struecker B, Katou S, Morguel MH, Pascher A. [Influence of molecular pathology on oncological surgery of liver and bile duct tumors]. Chirurg 2021;92:1003-10. [PMID: 34519849 DOI: 10.1007/s00104-021-01495-6] [Reference Citation Analysis]
140 Villanueva A, Luedde T. The transition from inflammation to cancer in the liver. Clin Liver Dis (Hoboken) 2016;8:89-93. [PMID: 31041071 DOI: 10.1002/cld.578] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
141 Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, Neumann UP, Lurje G. Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach. Int J Mol Sci 2019;20:E1465. [PMID: 30909504 DOI: 10.3390/ijms20061465] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 15.0] [Reference Citation Analysis]
142 Lünse S, Heidecke C, Partecke LI; Department of General Surgery, Visceral, Thoracic and Vascular Surgery, Universitätsmedizin Greifswald, Greifswald, Germany, Department of General Surgery, Visceral, Thoracic and Vascular Surgery, Universitätsmedizin Greifswald, Greifswald, Germany, Department of General, Visceral and Thoracic Surgery, Helios Klinikum Schleswig, Schleswig, Germany. Current Topics and Perspectives in Surgical Management of Hepatocellular Carcinoma. In: Tirnitz-parker JE, editor. Hepatocellular Carcinoma. Codon Publications; 2019. pp. 111-25. [DOI: 10.15586/hepatocellularcarcinoma.2019.ch6] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
143 Liu S, Li H, Guo L, Zhang B, Zhou B, Zhang W, Zhou J, Fan J, Ye Q. Tumor Size Affects Efficacy of Adjuvant Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Microvascular Invasion. Oncologist. 2019;24:513-520. [PMID: 30552155 DOI: 10.1634/theoncologist.2018-0305] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
144 Mehta N, Yao FY. Nucleos(t)ide analogs reduce the risk of hepatitis B-associated hepatocellular carcinoma: A can't miss proposition? Hepatology 2016;63:1415-7. [PMID: 26679367 DOI: 10.1002/hep.28404] [Reference Citation Analysis]
145 Kudo M. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. World J Gastroenterol 2019; 25(7): 789-807 [PMID: 30809080 DOI: 10.3748/wjg.v25.i7.789] [Cited by in CrossRef: 92] [Cited by in F6Publishing: 84] [Article Influence: 30.7] [Reference Citation Analysis]
146 Colquhoun SD. Hepatocellular carcinoma clinical update: Current standards and therapeutic strategies. Liver Research 2020;4:180-90. [DOI: 10.1016/j.livres.2020.11.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 Vogel A, Saborowski A. Adjuvant 131I-metuximab in hepatocellular carcinoma: a new option for an old drug? The Lancet Gastroenterology & Hepatology 2020;5:517-9. [DOI: 10.1016/s2468-1253(20)30004-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
148 Huang Y, Zhang Z, Zhou Y, Yang J, Hu K, Wang Z. Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy? Onco Targets Ther. 2019;12:541-548. [PMID: 30666133 DOI: 10.2147/ott.s187357] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
149 Chen Y, Zheng X, Wu C. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer. Front Immunol 2021;12:792691. [PMID: 34925375 DOI: 10.3389/fimmu.2021.792691] [Reference Citation Analysis]
150 Eggert T, Greten TF. Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma. Digestion 2017;96:1-4. [PMID: 28605745 DOI: 10.1159/000464282] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
151 Sun Y, Ma W, Yang Y, He M, Li A, Bai L, Yu B, Yu Z. Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy. Asian J Pharm Sci 2019;14:581-94. [PMID: 32104485 DOI: 10.1016/j.ajps.2019.04.005] [Cited by in Crossref: 65] [Cited by in F6Publishing: 49] [Article Influence: 21.7] [Reference Citation Analysis]
152 Sapir E, Tao Y, Schipper MJ, Bazzi L, Novelli PM, Devlin P, Owen D, Cuneo KC, Lawrence TS, Parikh ND, Feng M. Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2018;100:122-130. [PMID: 29066120 DOI: 10.1016/j.ijrobp.2017.09.001] [Cited by in Crossref: 66] [Cited by in F6Publishing: 50] [Article Influence: 13.2] [Reference Citation Analysis]
153 Alshahrani AA, Hwang S, Song GW, Moon DB, Jung DH, Ahn CS, Kim KH, Ha TY, Park GC, Ha SM, Park YH, Lee SG. Management of very late peritoneal metastasis of hepatocellular carcinoma 10 years after liver transplantation: Lessons from two cases. Ann Hepatobiliary Pancreat Surg 2018;22:136-43. [PMID: 29896574 DOI: 10.14701/ahbps.2018.22.2.136] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
154 Qin S, Li A, Yi M, Yu S, Zhang M, Wu K. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol 2019;12:27. [PMID: 30866992 DOI: 10.1186/s13045-019-0718-5] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 23.7] [Reference Citation Analysis]
155 Arvanitakis K, Koletsa T, Mitroulis I, Germanidis G. Tumor-Associated Macrophages in Hepatocellular Carcinoma Pathogenesis, Prognosis and Therapy. Cancers (Basel) 2022;14:226. [PMID: 35008390 DOI: 10.3390/cancers14010226] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
156 Teng KY, Han J, Zhang X, Hsu SH, He S, Wani NA, Barajas JM, Snyder LA, Frankel WL, Caligiuri MA, Jacob ST, Yu J, Ghoshal K. Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model. Mol Cancer Ther 2017;16:312-22. [PMID: 27980102 DOI: 10.1158/1535-7163.MCT-16-0124] [Cited by in Crossref: 51] [Cited by in F6Publishing: 37] [Article Influence: 8.5] [Reference Citation Analysis]
157 Huang D, Yuan W, Li H, Li S, Chen Z, Yang H. Identification of key pathways and biomarkers in sorafenib-resistant hepatocellular carcinoma using bioinformatics analysis. Exp Ther Med 2018;16:1850-8. [PMID: 30186410 DOI: 10.3892/etm.2018.6427] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
158 Zhang K, Tao C, Wu F, Siqin T, Wu J, Rong W. Establishment and Evaluation of a Predictive Model for Early Postoperative Recurrence of Hepatocellular Carcinoma in Patients with Microvascular Invasion. Int J Gen Med 2021;14:2259-74. [PMID: 34113155 DOI: 10.2147/IJGM.S303896] [Reference Citation Analysis]
159 Loosen SH, Castoldi M, Jördens MS, Roy S, Vucur M, Kandler J, Hammerich L, Mohr R, Tacke F, Ulmer TF, Neumann UP, Luedde T, Roderburg C. Serum levels of circulating microRNA-107 are elevated in patients with early-stage HCC. PLoS One 2021;16:e0247917. [PMID: 33711036 DOI: 10.1371/journal.pone.0247917] [Reference Citation Analysis]
160 Zhang Q, Chen Y, Bai X, Liang T. Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations. Front Oncol 2020;10:590058. [PMID: 33178615 DOI: 10.3389/fonc.2020.590058] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
161 Wang D, Sun Q, Wu J, Wang W, Yao G, Li T, Li X, Li L, Zhang Y, Cui W, Song S. A new Prenylated Flavonoid induces G0/G1 arrest and apoptosis through p38/JNK MAPK pathways in Human Hepatocellular Carcinoma cells. Sci Rep 2017;7:5736. [PMID: 28720813 DOI: 10.1038/s41598-017-05955-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
162 Alqahtani SA, Sanai FM, Alolayan A, Abaalkhail F, Alsuhaibani H, Hassanain M, Alhazzani W, Alsuhaibani A, Algarni A, Forner A, Finn RS, Al-Hamoudi WK. Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi J Gastroenterol 2020;26:S1-S40. [PMID: 33078723 DOI: 10.4103/sjg.SJG_477_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
163 Kloeckner R, Galle PR, Bruix J. Local and Regional Therapies for Hepatocellular Carcinoma. Hepatology 2021;73 Suppl 1:137-49. [PMID: 32557715 DOI: 10.1002/hep.31424] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 23.0] [Reference Citation Analysis]
164 Nagase Y, Hiramatsu K, Funauchi M, Shiomi M, Masuda T, Kakuda M, Nakagawa S, Miyoshi A, Matsuzaki S, Kobayashi E, Kimura T, Serada S, Ueda Y, Naka T, Kimura T. Anti-lipolysis-stimulated lipoprotein receptor monoclonal antibody as a novel therapeutic agent for endometrial cancer. BMC Cancer 2022;22:679. [PMID: 35729527 DOI: 10.1186/s12885-022-09789-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Tovoli F, Casadei-Gardini A, Benevento F, Piscaglia F. Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019. Dig Liver Dis 2019;51:1067-73. [PMID: 31208929 DOI: 10.1016/j.dld.2019.05.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
166 Liu T, Shen Y, Cheng A. Immune checkpoint inhibitors for hepatocellular carcinoma – A game changer in treatment landscape. Journal of the Formosan Medical Association 2022. [DOI: 10.1016/j.jfma.2022.03.017] [Reference Citation Analysis]
167 Kudo M. Systemic Therapy for Hepatocellular Carcinoma: Latest Advances. Cancers (Basel). 2018;10. [PMID: 30380773 DOI: 10.3390/cancers10110412] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 19.5] [Reference Citation Analysis]
168 Ban D, Ogura T, Akahoshi K, Tanabe M. Current topics in the surgical treatments for hepatocellular carcinoma. Ann Gastroenterol Surg 2018;2:137-46. [PMID: 29863117 DOI: 10.1002/ags3.12065] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
169 Erstad DJ, Razavi AA, Li S, Tanabe KK, Fuchs BC. Prevention Strategies for Hepatocellular Carcinoma. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 255-89. [DOI: 10.1007/978-3-030-21540-8_13] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
170 Altayar O, Shah R, Chang CY, Falck-Ytter Y, Muir AJ. AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma. Gastroenterology 2022;162:937-51. [PMID: 35210015 DOI: 10.1053/j.gastro.2021.12.275] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
171 Yu M, Wu T, Lee C, Lee Y, Lian J, Tsai C, Hsieh S, Tsai C. Percentage genome change and chromosome 7q amplification predict sorafenib response in advanced hepatocellular carcinoma. Biomedical Journal 2020. [DOI: 10.1016/j.bj.2020.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
172 Pinter M, Peck-Radosavljevic M. Review article: systemic treatment of hepatocellular carcinoma. Aliment Pharmacol Ther 2018;48:598-609. [PMID: 30039640 DOI: 10.1111/apt.14913] [Cited by in Crossref: 84] [Cited by in F6Publishing: 82] [Article Influence: 21.0] [Reference Citation Analysis]
173 Wang XH, Long LH, Cui Y, Jia AY, Zhu XG, Wang HZ, Wang Z, Zhan CM, Wang ZH, Wang WH. MRI-based radiomics model for preoperative prediction of 5-year survival in patients with hepatocellular carcinoma. Br J Cancer 2020;122:978-85. [PMID: 31937925 DOI: 10.1038/s41416-019-0706-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
174 Loosen SH, Wirtz TH, Roy S, Vucur M, Castoldi M, Schneider AT, Koppe C, Ulmer TF, Roeth AA, Bednarsch J, Alizai PH, Paffenholz P, Demir M, Trautwein C, Tacke F, Neumann UP, Roderburg C, Luedde T. Circulating levels of microRNA193a-5p predict outcome in early stage hepatocellular carcinoma. PLoS One 2020;15:e0239386. [PMID: 32960907 DOI: 10.1371/journal.pone.0239386] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
175 Anand AC, Acharya SK. New Developments in the Treatment of Hepatocellular Carcinoma: The Concept of Adjuvant and Neoadjuvant Chemotherapy. J Clin Exp Hepatol 2021;11:284-7. [PMID: 33994710 DOI: 10.1016/j.jceh.2021.04.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
176 Shi JJ, Dang SS. Recent advances in molecular targeted therapy of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2018; 26(34): 2008-2017 [DOI: 10.11569/wcjd.v26.i34.2008] [Cited by in CrossRef: 1] [Article Influence: 0.3] [Reference Citation Analysis]
177 D'Alessio A, Rimassa L, Cortellini A, Pinato DJ. PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects. J Hepatocell Carcinoma 2021;8:887-97. [PMID: 34386437 DOI: 10.2147/JHC.S284440] [Reference Citation Analysis]
178 Pascual S, Herrera I, Irurzun J. New advances in hepatocellular carcinoma. World J Hepatol 2016; 8(9): 421-438 [PMID: 27028578 DOI: 10.4254/wjh.v8.i9.421] [Cited by in Crossref: 92] [Cited by in F6Publishing: 80] [Article Influence: 15.3] [Reference Citation Analysis]
179 Petta S, Cabibbo G, Barbara M, Attardo S, Bucci L, Farinati F, Giannini EG, Tovoli F, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Colecchia A, Persico M, Boccaccio V, Craxì A, Bruno S, Trevisani F, Cammà C; Italian Liver Cancer (ITA.LI.CA) Group. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. Aliment Pharmacol Ther 2017;45:160-8. [PMID: 27790734 DOI: 10.1111/apt.13821] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 9.8] [Reference Citation Analysis]
180 Lock M, Meyers BM, Mujoomdar A. The addition of radiofrequency ablation for patients receiving sorafenib: new evidence for a new standard? Ann Transl Med 2021;9:3. [PMID: 33553296 DOI: 10.21037/atm-20-7474] [Reference Citation Analysis]
181 Wassmer CH, Moeckli B, Berney T, Toso C, Orci LA. Shorter Survival after Liver Pedicle Clamping in Patients Undergoing Liver Resection for Hepatocellular Carcinoma Revealed by a Systematic Review and Meta-Analysis. Cancers (Basel) 2021;13:637. [PMID: 33562666 DOI: 10.3390/cancers13040637] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
182 Song S, Bai M, Li X, Gong S, Yang W, Lei C, Tian H, Si M, Hao X, Guo T. Early Predictive Value of Circulating Biomarkers for Sorafenib in Advanced Hepatocellular Carcinoma. Expert Rev Mol Diagn 2022. [PMID: 35234564 DOI: 10.1080/14737159.2022.2049248] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
183 Cheng S, Chen M, Cai J; National Research Cooperative Group for Diagnosis and Treatment of Hepatocellular Carcinoma with Tumor Thrombus. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition. Oncotarget. 2017;8:8867-8876. [PMID: 27780939 DOI: 10.18632/oncotarget.12817] [Cited by in Crossref: 27] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
184 Sun Q, Zhang X, Gong X, Hu Z, Zhang Q, He W, Chang X, Hu Z, Chen Y. Survival analysis between laparoscopic and open hepatectomy for hepatocellular carcinoma: a meta-analysis based on reconstructed time-to-event data. Hepatol Int 2021. [PMID: 34258665 DOI: 10.1007/s12072-021-10219-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
185 McVey JC, Sasaki K, Firl DJ. Risk assessment criteria in liver transplantation for hepatocellular carcinoma: proposal to improve transplant oncology. Hepat Oncol 2020;7:HEP26. [PMID: 32774836 DOI: 10.2217/hep-2020-0003] [Reference Citation Analysis]
186 Singal AG, Rich NE, Mehta N, Branch AD, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Ioannou GN, Huang A, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Kagan S, Gopal P, Wong R, Parikh ND, Murphy CC. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology. 2019;157:1253-1263.e2. [PMID: 31374215 DOI: 10.1053/j.gastro.2019.07.040] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 17.7] [Reference Citation Analysis]
187 Gilabert M, Raoul JL. Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein. J Hepatocell Carcinoma 2018;5:91-8. [PMID: 30464931 DOI: 10.2147/JHC.S157413] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
188 Takami T, Yamasaki T, Saeki I, Matsumoto T, Suehiro Y, Sakaida I. Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function. World J Gastroenterol 2016; 22(32): 7252-7263 [PMID: 27621572 DOI: 10.3748/wjg.v22.i32.7252] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
189 Weinmann A, Galle PR. Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions. Curr Oncol 2020;27:S152-64. [PMID: 33343209 DOI: 10.3747/co.27.7315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
190 Shah C, Mramba LK, Bishnoi R, Bejjanki H, Chhatrala HS, Chandana SR. Survival differences among patients with hepatocellular carcinoma based on the stage of disease and therapy received: pre and post sorafenib era. J Gastrointest Oncol 2017;8:789-98. [PMID: 29184682 DOI: 10.21037/jgo.2017.06.16] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
191 Kudo M. Combination Cancer Immunotherapy in Hepatocellular Carcinoma. Liver Cancer. 2018;7:20-27. [PMID: 29662830 DOI: 10.1159/000486487] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
192 Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms. Z Gastroenterol 2022;60:e56-e130. [PMID: 35042248 DOI: 10.1055/a-1589-7568] [Reference Citation Analysis]
193 Agarwal PD, Lucey MR. Management of hepatocellular carcinoma recurrence after liver transplantation. Ann Hepatol 2021;:100654. [PMID: 34929349 DOI: 10.1016/j.aohep.2021.100654] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
194 Khan MW, Zhao P, Khan A, Raza F, Raza SM, Sarfraz M, Chen Y, Li M, Yang T, Ma X, Xiang G. Synergism of cisplatin-oleanolic acid co-loaded calcium carbonate nanoparticles on hepatocellular carcinoma cells for enhanced apoptosis and reduced hepatotoxicity. Int J Nanomedicine 2019;14:3753-71. [PMID: 31239661 DOI: 10.2147/IJN.S196651] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
195 Kim N, Seong J. Reply to: "Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?". J Hepatol 2020;73:468-9. [PMID: 32467075 DOI: 10.1016/j.jhep.2020.04.016] [Reference Citation Analysis]
196 Trojan J, Waidmann O. Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma. J Hepatocell Carcinoma. 2016;3:31-36. [PMID: 27703962 DOI: 10.2147/jhc.s112537] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
197 Ko AH. Moving from late to early stage disease: lessons learned from erlotinib in pancreatic cancer. Hepatobiliary Surg Nutr 2018;7:406-8. [PMID: 30498720 DOI: 10.21037/hbsn.2018.06.02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
198 Lee SK, Lee SW, Jang JW, Bae SH, Choi JY, Yoon SK. Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma. Int J Mol Sci 2021;22:10271. [PMID: 34638613 DOI: 10.3390/ijms221910271] [Reference Citation Analysis]
199 Foerster F, Galle PR. The Current Landscape of Clinical Trials for Systemic Treatment of HCC. Cancers (Basel) 2021;13:1962. [PMID: 33921731 DOI: 10.3390/cancers13081962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
200 Shang J, Xu S, Zhang J, Ran X, Bai L, Tang H. Efficacy of sorafenib in patients with hepatocellular carcinoma after resection: a meta-analysis. Oncotarget 2017;8:109723-31. [PMID: 29312642 DOI: 10.18632/oncotarget.21299] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
201 Doganay L. Hepatocellular Cancer: Is Recurrence Inevitable? J Gastrointest Cancer 2017;48:274-5. [PMID: 28647821 DOI: 10.1007/s12029-017-9967-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
202 Ishimaru N, Fujikawa H, Niwa K, Kobayashi Y, Kapoor S. A Rare Cause of Haemorrhagic Shock: Rupture of Gastric Wall Seeding of Hepatocellular Carcinoma. Case Reports in Hepatology 2022;2022:1-4. [DOI: 10.1155/2022/6560834] [Reference Citation Analysis]
203 Zhang W. Sorafenib in adjuvant setting: call for precise and personalized therapy. Transl Gastroenterol Hepatol 2016;1:13. [PMID: 28138580 DOI: 10.21037/tgh.2016.03.13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
204 Deng Q, He M, Fu C, Feng K, Ma K, Zhang L. Radiofrequency ablation in the treatment of hepatocellular carcinoma. Int J Hyperthermia 2022;39:1052-63. [PMID: 35944905 DOI: 10.1080/02656736.2022.2059581] [Reference Citation Analysis]
205 Li Z, Zhang H, Han J, Chen Y, Lin H, Yang T. Surface Nanopore Engineering of 2D MXenes for Targeted and Synergistic Multitherapies of Hepatocellular Carcinoma. Adv Mater 2018;30:e1706981. [PMID: 29663543 DOI: 10.1002/adma.201706981] [Cited by in Crossref: 111] [Cited by in F6Publishing: 93] [Article Influence: 27.8] [Reference Citation Analysis]
206 Feng SQ, Wang GJ, Zhang JW, Xie Y, Sun RB, Fei F, Huang JQ, Wang Y, Aa JY, Zhou F. Combined treatment with apatinib and docetaxel in A549 xenograft mice and its cellular pharmacokinetic basis. Acta Pharmacol Sin 2018;39:1670-80. [PMID: 29770798 DOI: 10.1038/aps.2018.16] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
207 Dian MJ, Li J, Zhang XL, Li ZJ, Zhou Y, Zhou W, Zhong QL, Pang WQ, Lin XL, Liu T, Liu YA, Li YL, Han LX, Zhao WT, Jia JS, Xiao SJ, Xiao D, Xia JW, Hao WC. MST4 negatively regulates the EMT, invasion and metastasis of HCC cells by inactivating PI3K/AKT/Snail1 axis. J Cancer 2021;12:4463-77. [PMID: 34149910 DOI: 10.7150/jca.60008] [Reference Citation Analysis]
208 Dai T, Deng M, Ye L, Lin G, Liu R, Deng Y, Li R, Liu W, Li H, Yang Y, Chen G, Wang G. Nomograms based on clinicopathological factors and inflammatory indicators for prediction of early and late recurrence of hepatocellular carcinoma after surgical resection for patients with chronic hepatitis B.Ann Transl Med. 2021;9:12. [PMID: 33553305 DOI: 10.21037/atm-20-1353] [Reference Citation Analysis]
209 Ziogas IA, Tsoulfas G. Evolving role of Sorafenib in the management of hepatocellular carcinoma. World J Clin Oncol 2017; 8(3): 203-213 [PMID: 28638790 DOI: 10.5306/wjco.v8.i3.203] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
210 Eilard MS, Andersson M, Naredi P, Geronymakis C, Lindnér P, Cahlin C, Bennet W, Rizell M. A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation. BMC Cancer 2019;19:568. [PMID: 31185950 DOI: 10.1186/s12885-019-5760-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
211 Yen C, Sharma R, Rimassa L, Arizumi T, Bettinger D, Choo HY, Pressiani T, Burlone ME, Pirisi M, Giordano L, Abdulrahman A, Kudo M, Thimme R, Park JW, Pinato DJ. Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study. Liver Cancer 2017;6:313-24. [PMID: 29234635 DOI: 10.1159/000480441] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
212 Miao W, Nie P, Yang G, Wang Y, Yan L, Zhao Y, Yu T, Yu M, Wu F, Rao W, Wang Z. An FDG PET/CT metabolic parameter-based nomogram for predicting the early recurrence of hepatocellular carcinoma after liver transplantation. Eur J Nucl Med Mol Imaging 2021. [PMID: 33813592 DOI: 10.1007/s00259-021-05328-w] [Reference Citation Analysis]
213 Desai GS, Pande PM, Narkhede RA, Wagle PK. Multimodality Management of Ruptured Large Hepatocellular Carcinoma and Its Recurrence: Rupture at Presentation Should Not Rupture Hope of Long-Term Survival. Surg J (N Y) 2020;6:e112-7. [PMID: 32566748 DOI: 10.1055/s-0040-1710530] [Reference Citation Analysis]
214 Wen T, Jin C, Facciorusso A, Donadon M, Han HS, Mao Y, Dai C, Cheng S, Zhang B, Peng B, Du S, Jia C, Xu F, Shi J, Sun J, Zhu P, Nara S, Millis JM; MDT of West China Hospital*. Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. Hepatobiliary Surg Nutr 2018;7:353-71. [PMID: 30498711 DOI: 10.21037/hbsn.2018.08.01] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
215 Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases: Marrero et al. Hepatology 2018;68:723-50. [DOI: 10.1002/hep.29913] [78495111110.1002/hep.29913','', '1948-5182')">Reference Citation Analysis]
216 Zhang W, Zhang B, Chen XP. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma. Front Med 2021;15:155-69. [PMID: 33754281 DOI: 10.1007/s11684-021-0848-3] [Reference Citation Analysis]
217 Roderburg C, Wree A, Demir M, Schmelzle M, Tacke F. The role of the innate immune system in the development and treatment of hepatocellular carcinoma. Hepat Oncol 2020;7:HEP17. [PMID: 32273975 DOI: 10.2217/hep-2019-0007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
218 Decraecker M, Toulouse C, Blanc JF. Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib. Cancers (Basel) 2021;13:6310. [PMID: 34944930 DOI: 10.3390/cancers13246310] [Reference Citation Analysis]
219 Yarchoan M, Agarwal P, Villanueva A, Rao S, Dawson LA, Llovet JM, Finn RS, Groopman JD, El-Serag HB, Monga SP, Wang XW, Karin M, Schwartz RE, Tanabe KK, Roberts LR, Gunaratne PH, Tsung A, Brown KA, Lawrence TS, Salem R, Singal AG, Kim AK, Rabiee A, Resar L, Hoshida Y, He AR, Ghoshal K, Ryan PB, Jaffee EM, Guha C, Mishra L, Coleman CN, Ahmed MM. Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. Cancer Res. 2019;79:4326-4330. [PMID: 31481419 DOI: 10.1158/0008-5472.can-19-0803] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 20.0] [Reference Citation Analysis]
220 Reichman TW, Bhati CS, Battula NR. Obtaining Optimal Long-Term Outcomes from Liver Transplantation for Hepatocellular Cancer. Dig Dis Sci 2019;64:976-84. [PMID: 30840163 DOI: 10.1007/s10620-019-05550-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
221 Kelley RK. Adjuvant sorafenib for liver cancer: wrong stage, wrong dose. Lancet Oncol 2015;16:1279-81. [PMID: 26433814 DOI: 10.1016/S1470-2045(15)00296-X] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
222 Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604. [PMID: 31439937 DOI: 10.1038/s41575-019-0186-y] [Cited by in Crossref: 1206] [Cited by in F6Publishing: 1102] [Article Influence: 402.0] [Reference Citation Analysis]
223 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
224 Akateh C, Black SM, Conteh L, Miller ED, Noonan A, Elliott E, Pawlik TM, Tsung A, Cloyd JM. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol 2019; 25(28): 3704-3721 [PMID: 31391767 DOI: 10.3748/wjg.v25.i28.3704] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 51] [Article Influence: 19.3] [Reference Citation Analysis]
225 Tovoli F, Negrini G, Benevento F, Faggiano C, Goio E, Granito A. Systemic treatments for hepatocellular carcinoma: challenges and future perspectives. Hepat Oncol 2018;5:HEP01. [PMID: 30302192 DOI: 10.2217/hep-2017-0020] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
226 Tampaki M, Papatheodoridis GV, Cholongitas E. Intrahepatic recurrence of hepatocellular carcinoma after resection: an update. Clin J Gastroenterol 2021;14:699-713. [PMID: 33774785 DOI: 10.1007/s12328-021-01394-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
227 Flynn MJ, Sayed AA, Sharma R, Siddique A, Pinato DJ. Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma. Hepatology 2019;69:2258-70. [PMID: 30382576 DOI: 10.1002/hep.30337] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 13.0] [Reference Citation Analysis]
228 von Felden J, Schulze K, Krech T, Ewald F, Nashan B, Pantel K, Lohse AW, Riethdorf S, Wege H. Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection. Oncotarget. 2017;8:89978-89987. [PMID: 29163804 DOI: 10.18632/oncotarget.21208] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
229 Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau GY, Mazzaferro V, Roayaie S, Lee HC, Kokudo N, Zhang Z, Torrecilla S, Moeini A, Rodriguez-Carunchio L, Gane E, Verslype C, Croitoru AE, Cillo U, de la Mata M, Lupo L, Strasser S, Park JW, Camps J, Solé M, Thung SN, Villanueva A, Pena C, Meinhardt G, Bruix J, Llovet JM. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut 2019;68:1065-75. [PMID: 30108162 DOI: 10.1136/gutjnl-2018-316408] [Cited by in Crossref: 103] [Cited by in F6Publishing: 91] [Article Influence: 34.3] [Reference Citation Analysis]
230 Wang M, Xi D, Ning Q. Virus-induced hepatocellular carcinoma with special emphasis on HBV. Hepatol Int. 2017;11:171-180. [PMID: 28097530 DOI: 10.1007/s12072-016-9779-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
231 Kudo M. Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives. Liver Cancer. 2017;6:101-112. [PMID: 28275577 DOI: 10.1159/000452138] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
232 Urban I, Primavesi F, Bogner K, Bartsch C, Trattner M, Schmid A, Stättner S. Hepatocellular carcinoma—neoadjuvant systemic and local treatment concepts to improve resectability rates and oncological outcome. memo 2022;15:5-11. [DOI: 10.1007/s12254-021-00791-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
233 Tao Y, Wang J, Xu X. Emerging and Innovative Theranostic Approaches for Mesoporous Silica Nanoparticles in Hepatocellular Carcinoma: Current Status and Advances. Front Bioeng Biotechnol 2020;8:184. [PMID: 32211399 DOI: 10.3389/fbioe.2020.00184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
234 Kim JM, Cho SY, Rhu J, Jung M, Her JH, Lim O, Choi GS, Shin EC, Hwang YK, Joh JW. Adjuvant therapy using ex vivo-expanded allogenic natural killer cells in hepatectomy patients with hepatitis B virus related solitary hepatocellular carcinoma: MG4101 study. Ann Hepatobiliary Pancreat Surg 2021;25:206-14. [PMID: 34053923 DOI: 10.14701/ahbps.2021.25.2.206] [Reference Citation Analysis]
235 Qu K, Liu T, Lin T, Zhang X, Cui R, Liu S, Meng F, Zhang J, Tai M, Wan Y, Liu C. Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis? Oncotarget 2016;7:67650-60. [PMID: 27588502 DOI: 10.18632/oncotarget.11767] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
236 Du J, Mao Y, Liu M, Tie Y, Huang H, Zhao J, Xiang Z, Luo D. Dose age affect the efficacy of molecular targeted agents in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget 2017;8:102413-9. [PMID: 29254256 DOI: 10.18632/oncotarget.22061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
237 Mei J, Li SH, Wang QX, Lu LH, Ling YH, Zou JW, Lin WP, Wen YH, Wei W, Guo RP. Resection vs. Sorafenib for Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Real World, Propensity Score Matched Analytic Study. Front Oncol 2020;10:573. [PMID: 32432036 DOI: 10.3389/fonc.2020.00573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
238 Sclafani F, Hendlisz A. Editorial: Adjuvant chemotherapy for gastrointestinal cancers: we can do much better. Curr Opin Oncol 2020;32:344-6. [PMID: 32541323 DOI: 10.1097/CCO.0000000000000638] [Reference Citation Analysis]
239 Schmid I, von Schweinitz D. Pediatric hepatocellular carcinoma: challenges and solutions. J Hepatocell Carcinoma 2017;4:15-21. [PMID: 28144610 DOI: 10.2147/JHC.S94008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 4.4] [Reference Citation Analysis]
240 Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, Lencioni R. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:293-313. [PMID: 33510460 DOI: 10.1038/s41575-020-00395-0] [Cited by in Crossref: 98] [Cited by in F6Publishing: 78] [Article Influence: 98.0] [Reference Citation Analysis]
241 Federico P, Petrillo A, Giordano P, Bosso D, Fabbrocini A, Ottaviano M, Rosanova M, Silvestri A, Tufo A, Cozzolino A, Daniele B. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives. Cancers (Basel) 2020;12:E3025. [PMID: 33080958 DOI: 10.3390/cancers12103025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
242 Zhu YJ, Zheng B, Wang HY, Chen L. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin 2017;38:614-22. [PMID: 28344323 DOI: 10.1038/aps.2017.5] [Cited by in Crossref: 282] [Cited by in F6Publishing: 262] [Article Influence: 56.4] [Reference Citation Analysis]
243 von Felden J, Heim D, Schulze K, Krech T, Ewald F, Nashan B, Lohse AW, Wege H. High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection. BMC Cancer 2017;17:60. [PMID: 28100188 DOI: 10.1186/s12885-017-3053-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
244 Zhou C, Chen W, Sun J, Atyah M, Yin Y, Zhang W, Guo L, Ye Q, Dong Q, Shi Y, Ren N. Low expression of WW domain-containing oxidoreductase associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection. Cancer Med 2018. [PMID: 29905011 DOI: 10.1002/cam4.1591] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
245 Ye JZ, Chen JZ, Li ZH, Bai T, Chen J, Zhu SL, Li LQ, Wu FX. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion. World J Gastroenterol 2017; 23(41): 7415-7424 [PMID: 29151695 DOI: 10.3748/wjg.v23.i41.7415] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 52] [Article Influence: 9.8] [Reference Citation Analysis]
246 Zhu XR, Zhu ML, Wang Q, Xue WJ, Wang YW, Wang RF, Chen SY, Zheng LZ. A case report of targeted therapy with apatinib in a patient with advanced gastric cancer and high serum level of alpha-fetoprotein. Medicine (Baltimore). 2016;95:e4610. [PMID: 27631210 DOI: 10.1097/md.0000000000004610] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
247 Xue M, Zhou C, Zheng Y, Zhang Z, Wang S, Fu Y, Atyah M, Xue X, Zhu L, Dong Q, Jia H, Ren N, Hu R. The association between KLF4 as a tumor suppressor and the prognosis of hepatocellular carcinoma after curative resection. Aging (Albany NY) 2020;12:15566-80. [PMID: 32756012 DOI: 10.18632/aging.103592] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
248 Chen QF, Li W, Yu SC, Chou YH, Rhim H, Yang X, Shen L, Dong A, Huang T, Huang J, Zhang F, Fan W, Zhao M, Gu Y, Huang Z, Zuo M, Zhai B, Xiao Y, Kuang M, Li J, Han J, Song W, Ma J, Wu P. Consensus of Minimally Invasive and Multidisciplinary Comprehensive Treatment for Hepatocellular Carcinoma - 2020 Guangzhou Recommendations. Front Oncol 2021;11:621834. [PMID: 34277397 DOI: 10.3389/fonc.2021.621834] [Reference Citation Analysis]
249 Chen B, Wu JX, Cheng SH, Wang LM, Rong WQ, Wu F, Wang SL, Jin J, Liu YP, Song YW, Ren H, Fang H, Tang Y, Li N, Li YX, Wang WH. Phase 2 Study of Adjuvant Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC. Hepatology 2021;74:2595-604. [PMID: 34097307 DOI: 10.1002/hep.31993] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
250 Santopaolo F, Lenci I, Milana M, Manzia TM, Baiocchi L. Liver transplantation for hepatocellular carcinoma: Where do we stand? World J Gastroenterol 2019; 25(21): 2591-2602 [PMID: 31210712 DOI: 10.3748/wjg.v25.i21.2591] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 30] [Article Influence: 10.0] [Reference Citation Analysis]
251 Liu LM, Lin P, Yang H, Dang YW, Chen G. Gene profiling of HepG2 cells following nitidine chloride treatment: An investigation with microarray and Connectivity Mapping. Oncol Rep 2019;41:3244-56. [PMID: 30942464 DOI: 10.3892/or.2019.7091] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
252 Zhang ZY, Zhang EL, Zhang BX, Zhang W. Surgery for hepatocellular carcinoma with tumor thrombosis in inferior vena cava: A case report. World J Clin Cases 2021; 9(36): 11495-11503 [DOI: 10.12998/wjcc.v9.i36.11495] [Reference Citation Analysis]
253 Pinato DJ, Fessas P, Sapisochin G, Marron TU. Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma. Hepatology 2021;74:483-90. [PMID: 33369758 DOI: 10.1002/hep.31697] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
254 Li X, Zhang D, Guan S, Ye W, Liu L, Lou L. Efficacy of anti-VEGF agents in the treatment of elderly hepatocellular carcinoma: a systematic review. Oncotarget 2017;8:93179-85. [PMID: 29190987 DOI: 10.18632/oncotarget.21452] [Reference Citation Analysis]
255 Makary MS, Ramsell S, Miller E, Beal EW, Dowell JD. Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons. World J Gastroenterol 2021; 27(43): 7462-7479 [PMID: 34887643 DOI: 10.3748/wjg.v27.i43.7462] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
256 Liao Y. Obstacles and opportunities in the prevention and treatment of HBV-related hepatocellular carcinoma. Genes Dis 2020;7:291-8. [PMID: 32884983 DOI: 10.1016/j.gendis.2019.12.014] [Reference Citation Analysis]
257 Piñero F, Thompson M, Marín JI, Silva M. Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients? World J Transplant 2020; 10(11): 297-306 [PMID: 33312891 DOI: 10.5500/wjt.v10.i11.297] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
258 Yuan BH, Li RH, Yuan WP, Yang T, Tong TJ, Peng NF, Li LQ, Zhong JH. Harms and benefits of adoptive immunotherapy for postoperative hepatocellular carcinoma: an updated review. Oncotarget. 2017;8:18537-18549. [PMID: 28061472 DOI: 10.18632/oncotarget.14507] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
259 Shi C, Li Y, Geng L, Shen W, Sui C, Dai B, Lu J, Pan M, Yang J. Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with microvascular invasion: A randomised controlled trial. Eur J Cancer 2022;166:176-84. [PMID: 35303509 DOI: 10.1016/j.ejca.2022.02.012] [Reference Citation Analysis]
260 Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther 2020;5:146. [PMID: 32782275 DOI: 10.1038/s41392-020-00264-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 11.5] [Reference Citation Analysis]
261 Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 96] [Cited by in F6Publishing: 108] [Article Influence: 96.0] [Reference Citation Analysis]
262 Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Ohgi K, Ohtsuka S, Aramaki T, Uesaka K. Changes in patient background and prognosis after hepatectomy for hepatocellular carcinoma by hepatitis virus infection status: New trends in Japan. Ann Gastroenterol Surg 2021;5:553-66. [PMID: 34337304 DOI: 10.1002/ags3.12451] [Reference Citation Analysis]
263 Sun X, Hou Z, Li N, Zhang S. MiR-597-5p suppresses the progression of hepatocellular carcinoma via targeting transcriptional enhancer associate domain transcription factor 1 (TEAD1). In Vitro Cell Dev Biol Anim 2022. [PMID: 35169903 DOI: 10.1007/s11626-021-00614-1] [Reference Citation Analysis]
264 Cho JY, Kwon SH, Lee EK, Lee JH, Kim HL. Cost-Effectiveness of Adjuvant Immunotherapy With Cytokine-Induced Killer Cell for Hepatocellular Carcinoma Based on a Randomized Controlled Trial and Real-World Data. Front Oncol 2021;11:728740. [PMID: 34926248 DOI: 10.3389/fonc.2021.728740] [Reference Citation Analysis]
265 Yan X, Fu X, Deng M, Chen J, He J, Shi J, Qiu Y. Infiltrative Hepatocellular Carcinoma: Assessment of Factors Associated With Outcomes in Patients Undergoing Hepatectomy. Medicine (Baltimore) 2016;95:e3589. [PMID: 27175659 DOI: 10.1097/MD.0000000000003589] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
266 Raoul JL, Adhoute X, Penaranda G, Perrier H, Castellani P, Oules V, Bourlière M. Sorafenib: Experience and Better Manage-ment of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis. Liver Cancer 2019;8:457-67. [PMID: 31799203 DOI: 10.1159/000497161] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
267 Makary MS, Khandpur U, Cloyd JM, Mumtaz K, Dowell JD. Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies. Cancers (Basel) 2020;12:E1914. [PMID: 32679897 DOI: 10.3390/cancers12071914] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
268 Orimo T, Kamiyama T, Wakayama K, Shimada S, Nagatsu A, Asahi Y, Sakamoto Y, Kamachi H, Taketomi A. Hepatectomy Combined with Diaphragmatic Resection for Hepatocellular Carcinoma with Diaphragmatic Involvement: A Propensity Score-Matched Analysis. Ann Surg Oncol 2020;27:4153-63. [PMID: 32588266 DOI: 10.1245/s10434-020-08754-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
269 Houron C, Danielou M, Mir O, Fromenty B, Perlemuter G, Voican CS. Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians. Crit Rev Oncol Hematol 2021;157:103127. [PMID: 33161366 DOI: 10.1016/j.critrevonc.2020.103127] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
270 El Dika I, Makki I, Abou-Alfa GK. Hepatocellular carcinoma, novel therapies on the horizon. Chin Clin Oncol 2021;10:12. [PMID: 32527116 DOI: 10.21037/cco-20-113] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
271 Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:525-43. [PMID: 33850328 DOI: 10.1038/s41575-021-00438-0] [Cited by in Crossref: 127] [Cited by in F6Publishing: 103] [Article Influence: 127.0] [Reference Citation Analysis]
272 Taketomi A. Clinical trials of antiangiogenic therapy for hepatocellular carcinoma. Int J Clin Oncol. 2016;21:213-218. [PMID: 26899258 DOI: 10.1007/s10147-016-0966-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
273 Rinninella E, Cerrito L, Spinelli I, Cintoni M, Mele MC, Pompili M, Gasbarrini A. Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives. J Clin Transl Hepatol 2017;5:235-48. [PMID: 28936405 DOI: 10.14218/JCTH.2017.00002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
274 Huang S, Li D, Zhuang L, Sun L, Wu J. A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection. World J Surg Oncol 2021;19:168. [PMID: 34112190 DOI: 10.1186/s12957-021-02280-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
275 Lang H, Heinrich S, Bartsch F, Hüttl F, Baumgart J, Mittler J. [Surgical treatment of hepatic tumors-liver resection and transplantation]. Internist (Berl) 2020;61:147-57. [PMID: 32016491 DOI: 10.1007/s00108-020-00754-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
276 Lin K, Wei F, Huang Q, Lai Z, Zhang J, Chen Q, Jiang Y, Kong J, Tang S, Lin J, Chen Y, Chen J, Zeng Y. Postoperative Adjuvant Transarterial Chemoembolization Plus Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma: a Multicentre Retrospective Study. JHC 2022;Volume 9:127-40. [DOI: 10.2147/jhc.s352480] [Reference Citation Analysis]
277 Bekric D, Ocker M, Mayr C, Stintzing S, Ritter M, Kiesslich T, Neureiter D. Ferroptosis in Hepatocellular Carcinoma: Mechanisms, Drug Targets and Approaches to Clinical Translation. Cancers (Basel) 2022;14:1826. [PMID: 35406596 DOI: 10.3390/cancers14071826] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
278 Gandhi M, Choo SP, Thng CH, Tan SB, Low AS, Cheow PC, Goh AS, Tay KH, Lo RH, Goh BK, Wong JS, Ng DC, Soo KC, Liew WM, Chow PK; Asia-Pacific Hepatocellular Carcinoma Trials Group. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial. BMC Cancer 2016;16:856. [PMID: 27821083 DOI: 10.1186/s12885-016-2868-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
279 Wei W, Jian PE, Li SH, Guo ZX, Zhang YF, Ling YH, Lin XJ, Xu L, Shi M, Zheng L, Chen MS, Guo RP. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. Cancer Commun (Lond) 2018;38:61. [PMID: 30305149 DOI: 10.1186/s40880-018-0331-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
280 Kudo M. Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials. Liver Cancer. 2019;8:221-238. [PMID: 31602367 DOI: 10.1159/000501501] [Cited by in Crossref: 16] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
281 Xu J, Wan Z, Tang M, Lin Z, Jiang S, Ji L, Gorshkov K, Mao Q, Xia S, Cen D, Zheng J, Liang X, Cai X. N6-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating β-catenin signaling. Mol Cancer 2020;19:163. [PMID: 33222692 DOI: 10.1186/s12943-020-01281-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 27] [Article Influence: 9.5] [Reference Citation Analysis]
282 Facciorusso A, Serviddio G, Muscatiello N. Local ablative treatments for hepatocellular carcinoma: An updated review. World J Gastrointest Pharmacol Ther 2016; 7(4): 477-489 [PMID: 27867681 DOI: 10.4292/wjgpt.v7.i4.477] [Cited by in CrossRef: 78] [Cited by in F6Publishing: 72] [Article Influence: 13.0] [Reference Citation Analysis]
283 Personeni N, Rimassa L. Exploring novel avenues for neoadjuvant treatment of hepatocellular carcinoma. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(21)00462-3] [Reference Citation Analysis]
284 Foerster F, Gairing SJ, Ilyas SI, Galle PR. Emerging immunotherapy for HCC: A guide for hepatologists. Hepatology 2022;75:1604-26. [PMID: 35253934 DOI: 10.1002/hep.32447] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
285 Wang D, Jia W, Wang Z, Wen T, Ding W, Xia F, Zhang L, Wu F, Peng T, Liu B, Zhou C, Zheng Q, Miao X, Peng J, Huang Z, Dou K. Retrospective analysis of sorafenib efficacy and safety in Chinese patients with high recurrence rate of post-hepatic carcinectomy. Onco Targets Ther 2019;12:5779-91. [PMID: 31410023 DOI: 10.2147/OTT.S168447] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
286 Erridge S, Sodergren MH. The Chengdu system for recurrent hepatocellular carcinoma: A step in the right direction.Hepatobiliary Surg Nutr. 2019;8:298-300. [PMID: 31245419 DOI: 10.21037/hbsn.2019.01.17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
287 Hoffman D, Mehta N. Recurrence of hepatocellular carcinoma following liver transplantation. Expert Rev Gastroenterol Hepatol 2021;15:91-102. [PMID: 32933351 DOI: 10.1080/17474124.2021.1823213] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
288 Liu B, Ding F, Liu Y, Xiong G, Lin T, He D, Zhang Y, Zhang D, Wei G. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients. Oncotarget 2016;7:67661-73. [PMID: 27602778 DOI: 10.18632/oncotarget.11813] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
289 Zane KE, Nagib PB, Jalil S, Mumtaz K, Makary MS. Emerging curative-intent minimally-invasive therapies for hepatocellular carcinoma. World J Hepatol 2022; 14(5): 885-895 [DOI: 10.4254/wjh.v14.i5.885] [Reference Citation Analysis]
290 Brown ZJ, Hewitt DB, Pawlik TM. Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress. Expert Opin Investig Drugs 2021;:1-13. [PMID: 34788184 DOI: 10.1080/13543784.2022.2008355] [Reference Citation Analysis]
291 Cheng S, Chen M, Cai J, Sun J, Guo R, Bi X, Lau WY, Wu M. Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition). Liver Cancer 2020;9:28-40. [PMID: 32071907 DOI: 10.1159/000503685] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
292 Moriguchi M, Umemura A, Itoh Y. Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma. Clin J Gastroenterol 2016;9:184-90. [PMID: 27401471 DOI: 10.1007/s12328-016-0670-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
293 Li L, Zhang H, Zhao H, Shi D, Zheng C, Zhao Y, Yang X. Radiofrequency-thermal effect of cisplatin-crosslinked nanogels for triple therapies of ablation-chemo-embolization. Chemical Engineering Journal 2022. [DOI: 10.1016/j.cej.2022.138421] [Reference Citation Analysis]
294 Donisi C, Puzzoni M, Ziranu P, Lai E, Mariani S, Saba G, Impera V, Dubois M, Persano M, Migliari M, Pretta A, Liscia N, Astara G, Scartozzi M. Immune Checkpoint Inhibitors in the Treatment of HCC. Front Oncol 2020;10:601240. [PMID: 33585218 DOI: 10.3389/fonc.2020.601240] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
295 Best J, Schotten C, Theysohn JM, Wetter A, Müller S, Radünz S, Schulze M, Canbay A, Dechêne A, Gerken G. Novel implications in the treatment of hepatocellular carcinoma. Ann Gastroenterol 2017;30:23-32. [PMID: 28042235 DOI: 10.20524/aog.2016.0092] [Cited by in Crossref: 3] [Cited by in F6Publishing: 16] [Article Influence: 0.5] [Reference Citation Analysis]
296 Bai L, Yi W, Chen J, Wang B, Tian Y, Zhang P, Cheng X, Si J, Hou X, Hou J. Two-Stage Targeted Bismuthene-Based Composite Nanosystem for Multimodal Imaging Guided Enhanced Hyperthermia and Inhibition of Tumor Recurrence. ACS Appl Mater Interfaces 2022;14:25050-64. [PMID: 35608833 DOI: 10.1021/acsami.2c01128] [Reference Citation Analysis]
297 Shang H, Chen Y, Wang C, Zhang S, Wu B, Liang X, Liu Z, Wang Q, Cheng W. RNA-Seq Technology Reveals the Mechanism of SDT Combined With Novel Nanobubbles Against HCC. Front Mol Biosci 2022;8:791331. [DOI: 10.3389/fmolb.2021.791331] [Reference Citation Analysis]
298 Schipilliti FM, Garajová I, Rovesti G, Balsano R, Piacentini F, Dominici M, Gelsomino F. The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review. Pharmaceuticals (Basel) 2021;14:43. [PMID: 33429973 DOI: 10.3390/ph14010043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
299 Zhu XD, Tang ZY, Sun HC. Targeting angiogenesis for liver cancer: Past, present, and future. Genes Dis 2020;7:328-35. [PMID: 32884987 DOI: 10.1016/j.gendis.2020.03.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
300 Galun D, Mijac D, Filipovic A, Bogdanovic A, Zivanovic M, Masulovic D. Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. JPM 2022;12:149. [DOI: 10.3390/jpm12020149] [Reference Citation Analysis]
301 Brown ZJ, Greten TF, Heinrich B. Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy. Hepatology 2019;70:1437-42. [PMID: 30927283 DOI: 10.1002/hep.30633] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 18.0] [Reference Citation Analysis]
302 Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9:452-463. [PMID: 32832496 DOI: 10.21037/hbsn-20-480] [Cited by in Crossref: 26] [Cited by in F6Publishing: 33] [Article Influence: 13.0] [Reference Citation Analysis]
303 Yang SY, Wang CC, Chen KD, Liu YW, Lin CC, Chuang CH, Tsai YC, Yao CC, Yen YH, Hsiao CC, Hu TH, Tsai MC. Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma. BMC Cancer 2021;21:70. [PMID: 33446127 DOI: 10.1186/s12885-021-07796-7] [Reference Citation Analysis]
304 Yang Y, Alderman C, Sehlaoui A, Xiao Y, Wang W. MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers. Can J Gastroenterol Hepatol 2018;2018:9740357. [PMID: 30046565 DOI: 10.1155/2018/9740357] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
305 Adhoute X, De Matharel M, Mineur L, Pénaranda G, Ouizeman D, Toullec C, Tran A, Castellani P, Rollet A, Oules V, Perrier H, Si Ahmed SN, Bourliere M, Anty R. Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching. World J Gastrointest Oncol 2022; 14(8): 1510-1527 [DOI: 10.4251/wjgo.v14.i8.1510] [Reference Citation Analysis]
306 Zhou Q, Wang X, Li R, Wang C, Wang J, Xie X, Li Y, Li S, Mao X, Liang P. Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis. J Gastroenterol 2022. [PMID: 35816221 DOI: 10.1007/s00535-022-01895-3] [Reference Citation Analysis]
307 Muzellec L, Bourien H, Edeline J. Patients' Experience of Systemic Treatment of Hepatocellular Carcinoma: A Review of the Impact on Quality of Life. Cancers (Basel) 2021;14:179. [PMID: 35008343 DOI: 10.3390/cancers14010179] [Reference Citation Analysis]
308 Li Q, Song T. Association Between Adjuvant Sorafenib and the Prognosis of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection. Front Oncol 2021;11:633033. [PMID: 34631511 DOI: 10.3389/fonc.2021.633033] [Reference Citation Analysis]
309 Sun R, Kong X, Qiu X, Huang C, Wong PP. The Emerging Roles of Pericytes in Modulating Tumor Microenvironment. Front Cell Dev Biol 2021;9:676342. [PMID: 34179005 DOI: 10.3389/fcell.2021.676342] [Reference Citation Analysis]
310 Li Z, Han J, Yu L, Qian X, Xing H, Lin H, Wu M, Yang T, Chen Y. Synergistic Sonodynamic/Chemotherapeutic Suppression of Hepatocellular Carcinoma by Targeted Biodegradable Mesoporous Nanosonosensitizers. Adv Funct Mater 2018;28:1800145. [DOI: 10.1002/adfm.201800145] [Cited by in Crossref: 95] [Cited by in F6Publishing: 72] [Article Influence: 23.8] [Reference Citation Analysis]
311 Tan HY, Wang N, Lam W, Guo W, Feng Y, Cheng YC. Targeting tumour microenvironment by tyrosine kinase inhibitor. Mol Cancer 2018;17:43. [PMID: 29455663 DOI: 10.1186/s12943-018-0800-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 10.5] [Reference Citation Analysis]
312 Yuan G, Wang L, Li J, Feng H, Ji J, Gu W, Shan B. Complexity in Clinical Trials: Blind Spots, Misleading Criteria, Winners and Losers. CCAND 2020;7:3-15. [DOI: 10.2174/2212697x06666191021125423] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
313 Iwagami Y, Casulli S, Nagaoka K, Kim M, Carlson RI, Ogawa K, Lebowitz MS, Fuller S, Biswas B, Stewart S, Dong X, Ghanbari H, Wands JR. Lambda phage-based vaccine induces antitumor immunity in hepatocellular carcinoma. Heliyon 2017;3:e00407. [PMID: 28971150 DOI: 10.1016/j.heliyon.2017.e00407] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
314 Chedid MF, Kruel CRP, Pinto MA, Grezzana-Filho TJM, Leipnitz I, Kruel CDP, Scaffaro LA, Chedid AD. Hepatocellular carcinoma: Diagnosis and operative management. Arq Bras Cir Dig. 2017;30:272-278. [PMID: 29340553 DOI: 10.1590/0102-6720201700040011] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
315 Okabe H, Yoshizumi T, Yamashita YI, Imai K, Hayashi H, Nakagawa S, Itoh S, Harimoto N, Ikegami T, Uchiyama H, Beppu T, Aishima S, Shirabe K, Baba H, Maehara Y. Histological architectural classification determines recurrence pattern and prognosis after curative hepatectomy in patients with hepatocellular carcinoma. PLoS One 2018;13:e0203856. [PMID: 30216361 DOI: 10.1371/journal.pone.0203856] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
316 Luo F, Li M, Ding J, Zheng S. The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. Front Oncol 2021;11:635731. [PMID: 34631513 DOI: 10.3389/fonc.2021.635731] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
317 Zayac A, Almhanna K. Hepatobiliary cancers and immunotherapy: where are we now and where are we heading? Transl Gastroenterol Hepatol. 2020;5:8. [PMID: 32190776 DOI: 10.21037/tgh.2019.09.07] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
318 Li CL, Ho MC, Lin YY, Tzeng ST, Chen YJ, Pai HY, Wang YC, Chen CL, Lee YH, Chen DS, Yeh SH, Chen PJ. Cell-Free Virus-Host Chimera DNA From Hepatitis B Virus Integration Sites as a Circulating Biomarker of Hepatocellular Cancer. Hepatology 2020;72:2063-76. [PMID: 32171027 DOI: 10.1002/hep.31230] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
319 Prieto-Domínguez N, Ordóñez R, Fernández A, Méndez-Blanco C, Baulies A, Garcia-Ruiz C, Fernández-Checa JC, Mauriz JL, González-Gallego J. Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy. J Pineal Res 2016;61:396-407. [PMID: 27484637 DOI: 10.1111/jpi.12358] [Cited by in Crossref: 80] [Cited by in F6Publishing: 86] [Article Influence: 13.3] [Reference Citation Analysis]
320 Han JW, Yoon SK. Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy. Pharmaceutics 2021;13:1387. [PMID: 34575463 DOI: 10.3390/pharmaceutics13091387] [Reference Citation Analysis]
321 Su GL, Altayar O, O'Shea R, Shah R, Estfan B, Wenzell C, Sultan S, Falck-Ytter Y. AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma. Gastroenterology 2022;162:920-34. [PMID: 35210014 DOI: 10.1053/j.gastro.2021.12.276] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
322 Dong L, Zhu K, Chen M, Li D, Jiang C, Chen L. Long non-coding RNA GACAT3 promotes liver cancer progression by regulating the proliferation, apoptosis and migration of tumor cells. Exp Ther Med 2020;19:3377-83. [PMID: 32266036 DOI: 10.3892/etm.2020.8604] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
323 Mohr R, Jost-Brinkmann F, Özdirik B, Lambrecht J, Hammerich L, Loosen SH, Luedde T, Demir M, Tacke F, Roderburg C. Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma. Front Immunol 2021;12:652172. [PMID: 33859646 DOI: 10.3389/fimmu.2021.652172] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
324 Zheng L, Gu X, Zheng G, Li X, He M, Liu L, Zhou X. Prediction of early recurrence and response to adjuvant Sorafenib for hepatocellular carcinoma after resection. PeerJ 2021;9:e12554. [PMID: 34900444 DOI: 10.7717/peerj.12554] [Reference Citation Analysis]
325 Llovet JM, Zucman-rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers 2016;2. [DOI: 10.1038/nrdp.2016.18] [78495111110.1038/nrdp.2016.18','', '1948-5182')">Reference Citation Analysis]
326 Forner A, Da Fonseca LG, Díaz-González Á, Sanduzzi-Zamparelli M, Reig M, Bruix J. Controversies in the management of hepatocellular carcinoma. JHEP Rep 2019;1:17-29. [PMID: 32039350 DOI: 10.1016/j.jhepr.2019.02.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
327 Aleman S. The hurdle with remaining risk for hepatocellular carcinoma in cirrhotic patients after a hepatitis C cure. Hepatol Med Policy 2016;1:11. [PMID: 30288315 DOI: 10.1186/s41124-016-0019-3] [Reference Citation Analysis]
328 Guo R, Wu Z, Wang J, Li Q, Shen S, Wang W, Zhou L, Wang W, Cao Z, Guo Y. Development of a Non-Coding-RNA-based EMT/CSC Inhibitory Nanomedicine for In Vivo Treatment and Monitoring of HCC. Adv Sci (Weinh) 2019;6:1801885. [PMID: 31065520 DOI: 10.1002/advs.201801885] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
329 Sun HC, Xie L, Yang XR, Li W, Yu J, Zhu XD, Xia Y, Zhang T, Xu Y, Hu B, Du LP, Zeng LY, Ouyang J, Zhang W, Song TQ, Li Q, Shi YH, Zhou J, Qiu SJ, Liu Q, Li YX, Tang ZY, Shyr Y, Shen F, Fan J. Shanghai Score: A Prognostic and Adjuvant Treatment-evaluating System Constructed for Chinese Patients with Hepatocellular Carcinoma after Curative Resection. Chin Med J (Engl) 2017;130:2650-60. [PMID: 29133751 DOI: 10.4103/0366-6999.218019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
330 Personeni N, Pressiani T, Santoro A, Rimassa L. Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications. Drugs Context. 2018;7:212533. [PMID: 30002715 DOI: 10.7573/dic.212533] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
331 Ye JZ, Wang YY, Bai T, Chen J, Xiang BD, Wu FX, Li LQ. Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the Asia-Pacific region beyond the Barcelona Clinic Liver Cancer treatment algorithms: a review and update. Oncotarget. 2017;8:93258-93278. [PMID: 29190996 DOI: 10.18632/oncotarget.18735] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
332 Le Grazie M, Biagini MR, Tarocchi M, Polvani S, Galli A. Chemotherapy for hepatocellular carcinoma: The present and the future. World J Hepatol 2017; 9(21): 907-920 [PMID: 28824742 DOI: 10.4254/wjh.v9.i21.907] [Cited by in Crossref: 96] [Cited by in F6Publishing: 91] [Article Influence: 19.2] [Reference Citation Analysis]
333 Zheng DH, Yang JM, Wu JX, Cheng SQ, Zhang SG, Wu D, Li AJ, Fu XH, Li X, Qi FC, Duan WH, Chen JH, Yang ZY, Liang L, Zeng JX, Zheng WD, Wu MC. Cidan Capsule in Combination with Adjuvant Transarterial Chemoembolization Reduces Recurrence Rate after Curative Resection of Hepatocellular Carcinoma: A Multicenter, Randomized Controlled Trial. Chin J Integr Med 2022. [PMID: 35915317 DOI: 10.1007/s11655-022-3537-4] [Reference Citation Analysis]
334 Bouattour M, Soubrane O, de Gramont A, Faivre S. Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM. Trials 2016;17:563. [PMID: 27887632 DOI: 10.1186/s13063-016-1675-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]